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ABSTRACT 
In proliferating cells, cell cycle arrest and DNA repair are induced upon detection of 
DNA damage. The DNA damage response (DDR) to double strand DNA breaks is 
mediated by phosphatidylinositol 3-kinase-like protein kinases (PIKKs), which 
propagate DDR signalling by phosphorylating SQ/TQ motifs in substrate proteins. Ciz1 
is a vertebrate protein previously shown to stimulate DNA replication initiation and 
facilitate cyclin exchange at pre-replication complexes. Ciz1 contains several SQ/TQ 
motif clusters, suggesting it is a PIKK substrate. This thesis investigates the potential 
role of Ciz1 in the DDR. 
A cell free system cell free system previously used to study DNA replication initiation 
was adapted to permit study of events resulting from etoposide-induced DNA damage. 
The system was characterised, and its potential as a screening tool to assess inhibitors of 
the DDR demonstrated, before being used to confirm PIKK-dependent phosphorylation 
of SQ/TQ motifs in both full length Ciz1 and a C-terminal domain fragment, Ciz1-
C274. This phosphorylation is inhibited by both wortmannin and LY294002, 
implicating DNA-PK as the responsible kinase.  More traditional methods including 
immunofluorescence and RT-PCR were used to characterise the effects of DDR 
signalling upon endogenous and overexpressed Ciz1. The resulting data show that Ciz1 
does not localise to foci of phosphorylated histone H2AX, unlike many known DDR 
signalling proteins. However etoposide treatment affected levels of C-terminal mRNA 
in intact cells, increasing transcription of exon 16 in WI38 cells, but decreasing overall 
mRNA levels in a cancer cell line. 
Instead the potential of Ciz1 to act as a modulator of DNA replication initiation through 
its established role in pre-replication complex assembly is discussed, and three models 
by which it may act are identified. I hypothesise that phosphorylation of Ciz1 stabilises 
cyclin E upon the pre-replication complex, preventing the CDK2-cyclin A complex 
from forming, and preventing origin licensing. 
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1.1 Introduction to the DNA damage response (DDR) 
1.1.1 The cell cycle 
In eukaryotes the majority of cells have exited the cell cycle, having reached their end 
fate from which they can fulfil their function. However for new tissues to grow, or to 
replace cells that have died, DNA replication must occur. The source of these new cells 
is normally either a stock of stem cells, or from progenitor cells that lie dormant within 
tissues and are induced to proliferate by extracellular signals such as hormones and 
growth factors (Coller, Sang et al. 2006). These restrictions on cellular proliferation 
limit the potential for DNA replication to a small proportion of the body’s cells, 
allowing control of development and repair of tissues, and guarding against the 
uncontrolled growth seen in diseases such as cancer. 
In order for a cell to duplicate itself, it must go through a series of carefully orchestrated 
events known as the cell cycle. These events are divided into two phases during which 
genomic DNA is first replicated and then distributed between the two daughter cells, 
with two intervening periods during which the cell both prepares itself for the next 
phase and resolves any problems arising during the previous phase. These phases are 
known as the first gap (G1) phase, synthesis (S) phase, second gap (G2) phase and 
mitosis (M) phase (Figure 1.1). 
Figure 1.1 Diagram of cell cycle progression showing active Cdk:cyclin 
complexes driving transitions between phases 
G0 
G2 S 
G1 
M 
Cdk1:cyclin A 
Cdk1:cyclin B 
Cdk1:cyclin A/B 
Cdk4/6:cyclin D 
Cdk2:cyclin E 
Cdk2:cyclin A 
R 
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Once a certain point in the cell’s preparation for division is reached, known as the 
restriction point (R), the cell no longer relies on external direction. From this point on 
the cell cycle is regulated by the cyclin dependent kinases (CDKs) and the cyclins. The 
CDKs are a family of serine-threonine kinases that are expressed throughout the cell 
cycle, but which only achieve an active conformation when bound to a cyclin binding 
partner. As cyclin levels fluctuate throughout the cell cycle this allows temporal control 
of events, with different CDK:cyclin complexes triggering different phases of the cell 
cycle (Figure 1.1) (Murray 2004). 
1.1.2 Accurate replication of DNA and repair of damage is vital to maintain 
integrity of the genome 
A key requirement for cellular proliferation is faithful maintenance of the genome - a 
process requiring both accurate replication of DNA during S phase, and repair of DNA 
damage that arises throughout the cell cycle. DNA damage arises constantly within the 
genome, due to both environmental factors, and as a consequence of cellular processes 
such as respiration and ATP hydrolysis. In differentiated cells, DNA repair takes place 
through a set of well-characterised mechanisms and is relatively straightforward, 
maintaining the stability of RNA and protein production. However in proliferating cells 
not only is there the need to repair damage before it can be passed on to daughter cells, 
but conflicting uses of the genome have the potential to interfere with or be affected by 
DNA repair. In such an instance the ability to halt the cell cycle is invaluable, and the 
signalling pathways used to do so are commonly called cell cycle checkpoints (Hartwell 
and Weinert 1989). Cell cycle checkpoints serve a number of other purposes in addition 
to DNA repair, with a classic example being the mitotic spindle checkpoint. During the 
spindle checkpoint, the Mad and Bub protein families delay the onset of anaphase upon 
detection of sister chromatids incorrectly attached to the microtubules linking them to 
the spindle poles, allowing defects to be resolved (Musacchio and Hardwick 2002; 
Musacchio and Salmon 2007). In the event of DNA damage, the chief purpose of cell 
cycle checkpoints is to halt DNA replication until repair has occurred, or to allow 
initiation of pathways that cause the cell to permanently cease cell division, such as 
senescence or programmed cell death.  
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Disease Gene Cancer predispositon 
Ataxia-telangiectasia ATM Leukaemia, lymphoma 
Nijmegen breakage 
syndrome NBS1 Leukaemia, lymphoma 
A-T-like disorder Mre11 Leukaemia, lymphoma 
Fanconi anaemia 
Brca2, FanCA, B, C, D1, 
D2, E, F, G, I, J, L, M & N Acute myelogenous leukaemias 
Familial breast, ovarian 
carcinoma syndrome Brca1, Brca2 Breast, ovarian & other cancers 
Li-Fraumeni syndrome p53 Chk2 
Sarcomas, leukaemia, brain, adrenal and 
other tumours 
Table 1.1: DDR genes and associated congenital diseases and cancer 
susceptibilities resulting from mutations (adapted from Kastan and Bartek 2004) 
 
1.1.3 Deregulation of damage detection and repair signalling is necessary for 
tumourigenesis  
In the event that cell cycle checkpoints and DNA repair mechanisms do not function 
correctly, build up of DNA damage in proliferating cells not only leads to 
developmental abnormalities, but is also a major contributing factor to carcinogenesis.  
Genes which increase susceptibility to cancer when mutated are divided into two classes 
– oncogenes, which when active promote tumour growth, and tumour suppressor genes, 
which safeguard against tumour growth when fully functional, and when inactivated 
permit the proliferation of cancerous cells. The genes involved in DNA damage 
detection and repair are classic examples of tumour suppressors, with congenital 
mutations often causing predisposition to the development of cancers, and are among 
the most commonly altered in tumor cells (Kastan and Bartek 2004). Selective pressure 
favours their mutation in these rapidly replicating cells, promoting tumorigenesis by 
allowing further deterioration of the genome (Gorgoulis, Vassiliou et al. 2005).  A 
summary of diseases caused by mutations in DDR genes and their associated cancer 
susceptibilities is shown in Table 1.1.  
There are three main cell cycle checkpoints at which DNA damage can be detected and 
repaired: the G2/M checkpoint blocking entry to M phase, the G1/S checkpoint 
blocking entry to S phase and the intra-S phase checkpoint which inhibits origin firing 
during S phase. These three checkpoints are shown in Figure 1.2. One of the key 
proteins involved in these proteins is one of the most commonly mutated DNA damage 
response checkpoint genes, p53, a transcription factor which is lost or altered in 50-55% 
of all human cancers (Hollstein, Rice et al. 1994). p53 activation in response to  stresses  
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Figure 1.2 Checkpoints halt the cell cycle upon detection of damage  
Diagram of cell cycle progression, showing simplified G2/M, G1/S, and intra-S 
checkpoint pathways following activation of ataxia telangiectasia mutated (ATM) 
and ATM and Rad3-related (ATR) by double strand breaks or single stranded DNA 
respectively. Adapted from RND systems DNA damage response mini review. 
http://www.rndsystems.com/mini_review_detail_objectname_MR03_DNADamageRe
sponse.aspx 
G2/M checkpoint: phosphatidylinositol 3-kinase-like protein kinase (PIKK) 
mediated activation of checkpoint kinase 1 (Chk1) and checkpoint kinase 2 (Chk2) 
causes them to phosphorylate cell division cycle 25 protein isoform C (Cdc25C), 
which binds to p53-activated 14-3-3 protein. The Cdc25C/14-3-3 complex is then 
sequestered in the cytoplasm, where Cdc25C is unable to activate the cyclin-
dependent kinase (CDK1)/cyclin B1 complex, thus preventing the cell from entering 
mitosis. 
G1/S checkpoint: Following activation of the PIKKs, the interaction of mini 
chromosome maintenance protein 2 (Mdm2) and p53, which normally results in 
nuclear export of p53 followed by its degradation, is blocked by phosphorylation of 
both proteins. The resulting accumulation of p53 in the nucleus causes up-regulation 
of p21, suppressing CDK2/cyclin E activity and preventing entry to S phase. 
Intra-S checkpoint: PIKK-mediated activation of Chk1 and Chk2 causes them to 
phosphorylate cell division cycle 25 protein isoform A (Cdc25A), targeting it for 
degradation. Cdc25A would normally dephosphorylate CDK2/cyclin E, but in its 
absence this cannot occur and the complex is not activated, preventing further firing 
of origins. Additionally phosphorylation of NBS1, BRCA1 and SMC1 by ATM is 
believed to contribute to delayed origin firing, although the precise mechanisms are 
as yet unknown. 
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such as DNA damage and hypoxia commonly leads to senescence or apoptosis of the 
cell, preventing carcinogenesis (Vousden and Lu 2002). p53 is vital for induction of the 
G1/S checkpoint, and also contributes to activation of the G2/M barrier (Agarwal, 
Agarwal et al. 1995). While inactivation of the p53 pathway disables the G1/S 
checkpoint and lowers the likelihood of apoptosis, it also leaves them more dependent 
on the intra-S phase checkpoint for repair of lesions.  
1.1.4 Knowledge of the DDR can be used to devise targeted therapies against 
cancer 
The lack of specificity of conventional cancer treatments means that while they are 
often effective at killing tumour cells, they also have many toxic effects on the rest of 
the body. This “collateral damage” is responsible for the characteristic symptoms of 
chemotherapy - loss of hair and depressed immune system due to the death of rapidly 
proliferating cells such as hair follicles and bone marrow progenitor cells - and can 
result in generation of secondary tumours later in life. There are a multitude of changes 
required for cancerous cells to arise, which were famously categorised by Hanahan and 
Weinberg in 2001 as the “hallmarks” of cancer, and updated in 2011 to reflect recent 
advances in understanding of the disease (Hanahan and Weinberg 2000; Hanahan and 
Weinberg 2011). These are self-sufficiency in growth signals, insensitivity to anti-
growth signals, tissue invasion and metastasis, limitless replicative potential, sustained 
angiogenesis, evasion of apoptosis, reprogramming of energy metabolism and evasion 
of immune destruction. 
An understanding of the genetic modifications driving and sustaining these changes is 
vital for the development of more focused treatments, which can exploit these 
differences to specifically identify and target tumour cells. Such treatments are 
commonly referred to as targeted therapies, and first arose in the 1970’s with the 
development of tamoxifen, an antioestrogenic molecule effective against breast cancers. 
As previously described, inactivation of p53 permits an escape from the threat of 
apoptosis in many human cancers, but leaves them reliant on alternate pathways to 
detect and repair the lethal DNA damage induced by chemotherapy and radiotherapy. If 
these pathways can be untangled targeted therapies can be devised to knock them out, 
leaving p53-deficient cells vulnerable to conventional therapies at lower doses, and 
patients with a decreased chance of developing secondary tumours. 
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1.1.5 The p53 and DNA damage response pathways are responsible for repair of 
double strand breaks 
There are several well characterised types of DNA damage, which can be divided into 
three main categories: 
• DNA base modifications - this category encompasses damage to nucleic acid 
base structure induced by oxidation, alkylation and hydrolysis, chemically 
induced adduct formation, UV induced generation of pyrimidine dimers and 
creation of mismatched bases by DNA replication error. Alkylation of DNA can 
occur either as a result of external exposure to alkylating agents such as methyl 
methanesulfonate and N-methyl-N'-nitro-N-nitrosoguanidine, or via exposure to 
compounds such as S-adenosylmethionine which arise as a result of biological 
processes. Presence of alkylated bases can lead to misincorporation during DNA 
replication, causing conversion of pyrimidines to purines. Repair of alkylative 
DNA damage is carried out either directly by alkyltransferase or dioxygenase 
enzymes, or by base excision repair (BER) or, more rarely, nucleic acid excision 
repair (NER) (Ura and Hayes 2002; Eker, Quayle et al. 2009). Oxidative damage 
to DNA arises due to exposure to exogenous factors such as ionising radiation, 
ultraviolet light (UV) and oxidising chemicals (Kryston, Georgiev et al.). 
Endogenous reactive oxygen species are also generated by mitochondria, 
peroxisomes and inflammatory cell activation as a by-product of biological 
processes (Klaunig, Xu et al. 1998).  Repair of oxidative DNA damage is mainly 
carried out by BER. DNA adducts occur as a result of exposure to polycyclic 
aromatic hydrocarbons such as benzo[a]pyrene. Once within the body, 
polycyclic aromatic hydrocarbons undergo metabolic activation by cytochrome 
P450-dependent oxidation forming highly reactive intermediates that covalently 
bind to DNA, forming adducts (Barkley, Ohmori et al. 2007). A second class of 
adduct, the 6-4-photoproduct, can also be formed as a result of exposure to UV 
light (Mitchell and Nairn 1989). Replication of DNA containing adducts is 
prone to errors and consequently results in mutations. Repair of adducts is 
carried out by BER and NER. 
• Crosslinking - interstrand crosslinks (ICLs) occur when the two strands of the 
DNA double helix are covalently linked to an intermediate chemical. ICLs are 
particularly cytotoxic, disrupting transcription and replication on both strands, 
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and as a complex form of damage, their repair involves genes from the NER, 
homologous recombination (HR) and Fanconi anemia (FA) pathways (McCabe, 
Olson et al. 2009). 
• DNA backbone damage - this category includes generation of abasic sites, and 
single and double strand breaks. Abasic sites are commonly created by 
spontaneous hydrolysis of the N-glycosilic bond, and can also arise as a product 
of repair of damaged or erroneous bases. They can block DNA transcription and 
replication, and are potentially mutagenic. They are normally repaired using the 
BER pathway (Boiteux and Guillet 2004). Single strand breaks (SSB) and 
double strand breaks (DSB) can arise as a consequence of errors during 
replication, or as a result of ionising radiation exposure. Some chemicals are 
also capable of interfering with replication fork progression, stalling active forks 
and inducing DSB formation. Double strand breaks are severely cytotoxic, 
presenting a barrier to DNA transcription and replication and, as both strands are 
severed, permit physical movement of the double helix that can lead to excision 
or duplication of entire chunks of the chromosome if wrongly rejoined. DSB can 
be repaired via non-homologous end joining (NHEJ), microhomology-mediated 
end joining or by HR, depending on the stage of the cell cycle during which they 
occur (Shrivastav, De Haro et al. 2008; Yun and Hiom 2009).   
Much of the research carried out on the DNA damage response to date has spanned a 
variety of model organisms, including yeasts, Xenopus, mice and humans. While there 
are similarities between the yeast and mammalian DDR signalling, with conservation of 
key players like the ATM-Chk2 pathway, there are also a number of unique proteins 
which play a major role in the higher eukaryotic DDR for which no yeast homolog 
exists, such as p53 (Carney, Maser et al. 1998; Matsuoka, Huang et al. 1998). In 
seeking to understand the pathways underlying human diseases, these proteins need to 
be taken into account, and this thesis will therefore concentrate on, and refer to models 
for the mammalian response to DNA damage.  
Furthermore, while the varying pathways of DNA damage repair are very interesting 
and present a large field of study, this thesis will focus on the processes that initially 
detect damage and induce a cellular response. As different types and causes of damage 
trigger different (albeit frequently overlapping) pathways, I will concentrate on one 
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specific type of damage and investigate the pathways by which one of the most severe 
forms of damage, double strand breaks, are detected. 
1.1.5.1 DSB detection and repair is mediated by multiple checkpoint pathways relying 
on shared initial signalling events 
While the DSB-response pathways shown in Figures 1.2 vary between checkpoints, 
they all rely upon one critical initial step to trigger their signalling cascades - activation 
of the phosphatidylinositol 3-kinase-like protein kinases (PIKKs), ataxia telangiectasia 
mutated (ATM), ATM and Rad3-related (ATR) and DNA-dependent protein kinase 
(DNA-PK). ATM primarily responds to direct induction of double strand breaks, while 
ATR tends to mediate responses to arrest of DNA replication forks, and creation of 
regions of single stranded DNA (ssDNA), which can then go on to form DSBs 
(Abraham 2001). Studies show that ATM is the dominant PIKK mediating DSB 
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Figure 1.3 Diagrams of common DNA lesions indicating cell cycle phase during 
which structures are likely to arise, and attendant PIKK 
Presence of undetected double or single strand breaks during G1 phase can lead to 
replication fork collapse once DNA replication begins. Adapted from Branzei et al 
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detection, but that DNA-PK also contributes to the response. DNA-PK plays only a 
small role in early signal propagation, and instead appears to mainly be involved in 
phosphorylation of E2F-1, a transcription factor controlling the transition from G1 to S 
phase, and in repair of DSBs by non-homologous end joining (Watanabe, Shinohara et 
al. 2003; Stiff, O'Driscoll et al. 2004; Dobbs, Tainer et al. 2010). A summary of 
common PIKK-mediated DNA lesions is shown in Figure 1.3 (Branzei and Foiani 
2008).  
1.1.5.2 ATM recruits DDR signalling factors to phosphorylated histone H2AX 
In mammals, activation of ATM occurs within a minute of DSB formation (Andegeko, 
Moyal et al. 2001), and is facilitated by the recruitment of the Mre11-Rad50-NBS1 
(MRN) complex to the lesion (Lee and Paull 2005; Paull and Lee 2005). Upon 
recruitment to the site of the DSB, ATM is autophosphorylated (Berkovich, Monnat et 
al. 2007) and in turn phosphorylates histone H2AX. Mediator of DNA damage 
checkpoint protein 1 (MDC1) binds to phosphorylated H2AX (γH2AX), and acts as a 
platform to which proteins independently recruited to the damaged site attach, allowing 
ATM to further phosphorylate neighbouring H2AX (Figure 1.4a) (Lou, Chini et al. 
2003; Peng and Chen 2005). These foci act as a centre for damage signalling and repair 
proteins, and their rapid formation and subsequent spread across megabase-sized 
regions of chromatin makes γH2AX a commonly used molecular marker of the DDR. 
Additionally ATM directly phosphorylates the effector protein Chk2 (Ahn, Li et al. 
2002). 
1.1.5.3 ATM also activates ATR signalling following DNA damage 
ATM also phosphorylates CtIP, leading to its recruitment to the break site (You and 
Bailis 2010). CtIP facilitates resectioning of DNA around the break to generate short 
single-stranded regions to which replication protein A (RPA) binds (You, Shi et al. 
2009). The presence of RPA stimulates binding of ATR interacting protein (ATRIP) to 
ssDNA, which exists as a stable complex with ATR in human cells, allowing formation 
of an ATR-ATRIP-ssDNA complex and stimulating phosphorylation of ATR (Figure 
1.4b) (Cortez, Guntuku et al. 2001; Zou and Elledge 2003). ATR goes on to 
phosphorylate Chk1, while phosphorylated CtIP signals the expression of cell cycle 
inhibitor genes including p21 and GADD45 (Li, Ting et al. 2000; Zou and Elledge 
2003). CtIP also regulates which repair method is used for double strand breaks - during 
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the S and G2 phases, HR is favoured, due to a lower rate of error, but following mitosis, 
changes in chromatin structure necessitate a switch to non-homologous end-joining or 
microhomology-mediated end-joining. RPA-dependent recruitment of ATR to ssDNA 
is also required for ATR’s involvement in ATM-independent detection and repair of 
other forms of DNA lesions (Zou and Elledge 2003).  
1.1.5.4 Following initial detection of damage, signal propagation is controlled by the 
mediator and effector proteins 
Despite their similar names the effector proteins, Chk1 and Chk2, share few structural 
features and are not closely related in sequence, but they are both serine-threonine 
kinases that relay the DDR signalling cascade initiated by the PIKKs (Bartek and Lukas 
2003). Chk1 mainly interacts with ATR, whereas Chk2 is activated chiefly by ATM. 
Figure 1.4 Early stages of ATM and ATR-mediated DNA damage detection 
a) Schematic of propagation of H2AX phosphorylation by ATM in response to DSB 
formation. The MRN complex is recruited to the site of the double strand break, 
allowing recruitment and autophosphorylation of ATM. Phosphorylation of nearby 
H2AX by ATM recruits MDC1, which acts as a tether for proteins recruited by ATM 
and the MRN complex, allowing foci of damage signalling and repair proteins to 
spread across the surrounding chromatin.  
b) Schematic of recruitment of ATR to ssDNA. Exposed ssDNA is coated by RPA, 
to which ATRIP and ATR bind, activating ATR and allowing recruitment of damage 
signalling and repair proteins. 
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Despite their specificity to individual PIKKs, many of the substrates of Chk1 and Chk2 
are shared, allowing similar checkpoint pathways to be activated in response to single 
and double strand breaks, despite varying requirements for repair pathways. In addition, 
the Chk proteins are soluble and remain present throughout the nucleus rather than 
localising solely to sites of damage, allowing propagation of signalling throughout the 
nucleus (Bartek and Lukas 2003; Lukas, Falck et al. 2003; Bekker-Jensen, Lukas et al. 
2006). Between them the Chks affect processes as diverse as damage-induced 
transcription, DNA repair, cell cycle arrest, apoptosis and chromatin remodelling via 
proteins including CDC25, p53, the tousled-like kinases, Pml, breast cancer 1 (Brca1) 
and E2F1 (Shieh, Ahn et al. 2000; Yang, Kuo et al. 2002; Groth, Lukas et al. 2003; 
Stevens, Smith et al. 2003; Karlsson-Rosenthal and Millar 2006; Zhuang, Zhang et al. 
2006).  
Throughout the DNA damage response, the signalling initiated by the PIKKs and Chks 
is mediated by checkpoint mediator proteins. While the effectors are dispersed 
throughout the nucleus, mediators act locally to DNA lesions, regulating PIKK activity 
and interactions and contributing to recruitment and assembly of protein complexes in 
the chromatin regions adjacent to sites of damage. The foci of damage signalling and 
repair proteins that are orchestrated by these mediators are commonly known as 
ionising radiation induced foci (IRIF), and co-localise with phosphorylated H2AX. 
MDC1 and the MRN complex, which facilitate and propagate phosphorylation of 
H2AX by ATM, are mediators, as are proteins such as Brca1, 53BP1, Brit1 and claspin 
(Harper and Elledge 2007). A common feature of mediator proteins is the presence of 
multiple Brca1 C-terminal (BRCT) domains in their C-terminal region (Huyton, Bates 
et al. 2000; Shang, Bodero et al. 2003; Lin, Liang et al. 2010; Watts and Brissett 2010). 
The BRCT domain has been shown to act as a phospho-protein binding domain, 
potentially facilitating interaction of the checkpoint mediators with other proteins 
phosphorylated by ATM, ATR, Chk1 and Chk2 (Yu, Chini et al. 2003). Mediators are 
frequently tumour suppressors or oncogenes, and their loss or mutation contributes to 
carcinogenesis (Kastan and Bartek 2004; Harper and Elledge 2007; Lowndes 2010). 
1.2 The Ciz1 protein 
P21Cip1/Waf1-interacting zinc finger protein 1 (Ciz1) is a member of the matrin family of 
nuclear proteins. Ciz1 was first characterised in 1999 through its interactions with the 
p21/CDK2 complex (Mitsui, Matsumoto et al. 1999), then independently isolated and 
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characterised as NP94 in 2003 (Warder and Keherly 2003). This study found expression 
within a variety of tissue types and demonstrated colocalisation with DNA, identifying 
a weak consensus DNA-binding sequence for Ciz1. Ciz1 was also independently 
identified as a cyclin A-responsive protein involved in the promotion of mammalian 
DNA replication (Coverley, Marr et al. 2005). Ciz1 homologues have been found in 
vertebrates such as mouse, chimpanzees, rats and pufferfish, but not in lower eukaryotes 
(Coverley, Marr et al. 2005). Over the past decade understanding of Ciz1’s function has 
been greatly improved, largely (but not exclusively) through the work of the Coverley 
laboratory at the University of York. 
 1.2.1 Ciz1 promotes DNA replication initiation  
The most extensively characterized role identified for Ciz1 is in cell cycle progression, 
specifically control of DNA replication initiation.  
1.2.1.1 Faithful replication of DNA requires spatial and temporal control of origins 
Unlike bacteria, which use a single origin from which to replicate the entire genome, the 
size of the eukaryotic genome and the complexity of its replication machinery 
necessitate use of multiple origins of replication. The mammalian genome therefore 
possesses between 30,000-50,000 origins per cell cycle, not all of which are active 
concurrently (Huberman and Riggs 1966). To further complicate matters, an excess of 
replication origins exists with only a subset of the full number being used during each 
cell cycle (Li, Bogan et al. 2000). In order for replication to take place, the cell must 
choose both which origins are to be used and in which order they are to be activated. 
The different types of replication origin and the factors surrounding their selection are 
reviewed by Méchali (Mechali 2011), but the process can be summarised as involving 
two key checkpoints. Firstly the origin decision point, during which the origins to be 
used are selected, and secondly the timing decision point, during which origins are 
divided into early-, mid- and late-S phase firing (Wu and Gilbert 1997; Dimitrova and 
Gilbert 1999; Li, Chen et al. 2001). 
1.2.1.2 Origin-licensing is controlled by CDK2:cyclin E 
Once origins are selected, they are licensed by the assembly of pre-replication 
complexes (pre-RC) containing the basic structure necessary for unwinding of DNA and 
loading of DNA polymerases (Blow and Hodgson 2002). These pre-replication 
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complexes are targeted to the site of origins by the origin replication complex (ORC) a 
six protein complex which binds to DNA at the sites of origins (Bell and Stillman 
1992). ORC then recruits Cdc6, and together ORC and Cdc6 promote loading of a 
complex made up of MCM2-7, a helicase, and Cdt1 onto the DNA (Tsakraklides and 
Bell 2010). At this point the pre-replication complex is fully assembled, and the origin 
is referred to as “licensed”, but it is not yet activated for replication. Dividing licensing 
and activation of origins into two temporally distinct phases allows the cell to prevent 
rereplication, as pre-replication complexes are disassembled following DNA 
replication, preventing further initiation at the fired origin (Arias and Walter 2007). 
Origin licensing is regulated by the Cdk2:cyclin E complex, which promotes loading of 
MCM2-7 onto the pre-replication complex and protectively phosphorylates Cdc6, 
preventing its degradation by licensing inhibitors (Furstenthal, Kaiser et al. 2001; 
Coverley, Laman et al. 2002; Geng, Yu et al. 2003; Mailand and Diffley 2005).  
1.2.1.3 Origin firing is controlled by CDK2:cyclin A and DDK 
Activation of origins is carried out by recruitment of proteins that activate MCM2-7, 
allowing unwinding of DNA to commence (Takeda and Dutta 2005). The first stage of 
this is the recruitment of MCM10 to the complex, and phosphorylation of MCM2-7 by 
Dbf4-dependent kinase (DDK), both of which promote loading of Cdc45 (Gregan, 
Lindner et al. 2003; Sheu and Stillman 2006). The other key set of proteins in activation 
of the pre-replication complex are the GINS complex, a ring-like structure which may 
coordinate DNA polymerases at the replication fork (Hubscher, Maga et al. 2002; De 
Falco, Ferrari et al. 2007). Origin firing is also controlled by a second kinase, the 
Cdk2:cyclin A complex. The precise targets of Cdk2:cyclin A are as yet undefined, but 
the complex has repeatedly been shown to be necessary for origin firing (Coverley, 
Laman et al. 2002; Katsuno, Suzuki et al. 2009; Nakanishi, Katsuno et al. 2010). 
1.2.1.4 Ciz1 stimulates initiation of DNA synthesis both in vitro and in intact cells 
Ciz1’s role in initiation has been explored using a cell free system permitting 
quantification of the number of nuclei initiating DNA replication. Cell free DNA 
replication systems were originally developed using viral control elements (Stillman 
1989) and later, activated Xenopus egg cells (Murray and Kirschner 1989). These 
systems allowed study of enzymatic and regulatory features of replication, but because 
of the nature of their components, did not permit study of the structural organisation or  
A B 
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Figure 1.5 Maps of human Ciz1  
a) Full schematic of translated exons, showing SQ/TQ motifs and functional domains 
as defined by a range of published and unpublished studies into Ciz1. Amino acid 
positions of characterised features of Ciz1 are given, along with references. Exon 
numbers marked with an asterisk indicate observation of alternate splicing or exon 
skipping in diseased tissue or tumour-derived cell lines. The replication and anchor 
domains displayed have been shown to undergo uncoupled transcription during 
cellular differentiation and tumourigenesis. 
b) Schematic of untranslated region preceding exon 2, showing location of partial 
(1/2) and full estrogen response elements (ERE). Exon 1 appears to be an 
untranslated region with the first translational start site in exon 2. Adapted from Den 
Hollander and Kumar, 2006. 
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regulatory events specific to the somatic cell cycle in differentiated cells. The system 
used by the Coverley laboratory to study initiation is instead derived from mammalian 
cells, allowing the combination of cytosolic extracts with isolated nuclei, which are then 
incubated with fluorescently labelled nucleotides. The mixture can then be examined by 
microscopy to determine the number of nuclei that have incorporated labelled 
nucleotides, allowing study of the initiation of DNA replication in G1 phase, and of 
replication elongation in S phase nuclei (Krude, Jackman et al. 1997; Coverley, Laman 
et al. 2002; Coverley, Marr et al. 2005).  
Addition of purified Ciz1 to this system demonstrated that Ciz1 increases the number of 
nuclei that undergo initiation, while transfection of a Ciz1 overexpression vector into 
cell lines in culture stimulated the number of cells that incorporate bromodeoxyuridine 
(BrdU) (Coverley, Marr et al. 2005). Stimulation of in vitro DNA synthesis has only 
previously been observed with proteins known to be involved in DNA replication 
(Coverley, Laman et al. 2002). Mutation of the CDK phosphorylation site T191 (Figure 
1.5a) in ECiz1 (an embryonic splice variant of Ciz1) increased the range of 
concentrations at which initiation was stimulated in this cell free system (Coverley, 
Marr et al. 2005), suggesting that its function is regulated by the cell cycle machinery. 
In addition to its capacity to stimulate initiation in vitro, endogenous Ciz1 forms nuclear 
foci during S phase (Coverley, Marr et al. 2005) which partially co-localise with 
proliferating cell nuclear antigen (PCNA), a cofactor of DNA polymerase δ (Moldovan, 
Pfander et al. 2007), and with early sites of DNA synthesis (Ainscough, Rahman et al. 
2007). 
1.2.2 Dissection of the role of Ciz1 in initiation  
Closer investigation of this stimulation of DNA replication initiation has shown that 
Ciz1 is necessary for cell cycle progression, with siRNA depletion of Ciz1 from cells 
inhibiting their entry to S phase (den Hollander and Kumar 2006). However pre-RC 
assembly on to chromatin is unaffected, with MCM3 recruitment to detergent-resistant 
nuclear structures increasing when Ciz1 is depleted (Coverley, Marr et al. 2005). This 
suggests that pre-replication complexes persist for a longer period in the absence of 
Ciz1, placing its function in between pre-RC assembly and conversion to active 
replication complexes. It was also shown that only soluble Ciz1 was affected by siRNA 
depletion, implying that newly synthesized Ciz1 is needed for DNA replication 
initiation and cell cycle progression to take place (Coverley, Marr et al. 2005). 
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Insoluble, nuclear matrix-associated Ciz1 remained unaffected, suggesting that this 
fraction may persist from previous cell cycles.  
1.2.2.1 Ciz1 interacts with cyclins A and E 
Ciz1 contains five Cy-motifs, domains with which the cyclin family of proteins are 
known to interact (Figure 1.5a) (Wohlschlegel, Dwyer et al. 2001). As cyclins E and A 
have major roles in the transition between G1 and S phase, with CDK2 swapping 
binding partners from cyclin E to cyclin A, these Cy-motifs seemed a potential 
candidate to explain Ciz1’s role in initiation, and have been scrutinised in detail 
(Coverley, Laman et al. 2002; Woo and Poon 2003). Recent data shows that Ciz1 
interacts with both cyclins, and that cyclin A displaces Ciz1-bound cyclin E in vitro 
(Copeland, Sercombe et al. 2010). A model for Ciz1’s interactions with the cyclins has 
been suggested, proposing that Ciz1 supports the sequential accumulation of cyclins E 
and A at the pre-replication complex during its assembly and activation. This model is 
given further weight by the fact that levels of Cdk2 activity are also reduced in breast 
cancer cells when Ciz1 is depleted (den Hollander and Kumar 2006).  
1.2.2.2 The C-terminal domain of Ciz1 does not stimulate DNA synthesis, but acts as a 
nuclear matrix anchor  
The model of Ciz1 as a platform for cyclin exchange during origin licensing and 
assembly also incorporates the possibility that Ciz1 spatially regulates cyclin A. 
Experiments using truncated forms of Ciz1 have shown that the C-terminal domain of 
Ciz1 is not required for stimulation of DNA replication, but that in its absence Ciz1 
does not form nuclear foci. This region is required for recruitment of Ciz1 to insoluble 
DNase 1 resistant foci within the nucleus during S phase (Ainscough, Rahman et al. 
2007). DNase I resistant non-chromatin protein/RNA structures are commonly known 
as the nuclear matrix, and are known to be enriched with replication origins during G1 
phase (Djeliova, Russev et al. 2001). As such, Ciz1 can be divided into two main 
domains – an N-terminal replication domain (RD) which promotes initiation via 
interaction with cyclins, and a C-terminal anchor domain (AD) responsible for correct 
localisation of Ciz1 within the nucleus (Figure 1.5a) – and it is believed that these two 
regions cooperate to ensure correct targeting of cyclin A to the nuclear matrix during 
pre-RC activation. 
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1.2.3 Several proteins that interact with p21 have been linked with Ciz1 
p21 is known to be vital for the arrest of the cell cycle as part of the DDR (Roninson 
2002), and Ciz1 was originally identified by virtue of its interaction with the protein 
(Mitsui, Matsumoto et al. 1999). It is known that Ciz1’s role in DNA replication is not 
dependent on p21, as Ciz1 overexpression stimulates synthesis of DNA even in p21 null 
cells (Coverley, Marr et al. 2005). This shows that Ciz1 does not promote DNA 
replication by sequestration of p21, and suggests that the interaction of the two proteins 
could play another role in the cell. Recent research has fuelled speculation over which 
mechanisms and functions this interaction could influence. 
1.2.3.1 Ciz1 interacts with dynein light chain 1 
The N-terminal region of Ciz1 binds dynein light chain 1 (DLC1) (den Hollander and 
Kumar 2006), an estrogen-regulated component of the cytoplasmic dynein motor 
involved in organelle transport within the cytoplasm (Hirokawa, Noda et al. 1998). 
DLC1 has been implicated in breast cancer tumourigenesis (Vadlamudi, Bagheri-
Yarmand et al. 2004) and overexpression is known to promote the G1-S phase transition 
by promoting Cdk2 kinase activity. This is stimulated by targeting of p21 to the nuclear 
compartment by DLC1, and does not occur when the Ciz1 binding domain of DLC1 is 
deleted (den Hollander and Kumar 2006). A model has been suggested in which DLC1 
transports Ciz1 to the nucleus, where Ciz1 binds p21 and Cdk2. Ciz1 and DLC1 
together target p21 to the cytoplasm, leading to increased Cdk2 activity. While this is 
supported by observations that overexpression of both p21 and Ciz1 induced 
cytoplasmic localisation of p21 (Mitsui, Matsumoto et al. 1999), it should be noted that 
these conclusions are drawn solely from protein overexpression in cancer cell lines, in 
which the DNA replication and repair processes are damaged. Thus the observations 
may not reflect the pathways used in healthy cells. Furthermore as Ciz1 has already 
been shown to promote entry to S phase in p21 null cells (Coverley, Marr et al. 2005), it 
seems unlikely that the trimer formed between DLC1, Ciz1 and p21 and any subsequent 
changes in localisation of proteins are involved in pre-RC assembly and stimulation of 
CDK2 activity. 
1.2.3.2 Ciz1 interacts with human enhancer of rudimentary 
Ciz1 also interacts with human enhancer of rudimentary (ERH) (Lukasik, Uniewicz et 
al. 2008). Increased levels of ERH mRNA observed in more rapidly proliferating 
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mammalian cell lines, and observed in vitro phosphorylation of Drosophila ERH by 
casein kinase II suggest that ERH may be involved in cell cycle progression 
(Gelsthorpe, Pulumati et al. 1997). ERH may be regulated by casein kinase II, a protein 
kinase targeting many transcription factors and regulators involved in the cell cycle. The 
ERH and p21 binding sites in Ciz1 are known to overlap (Figure 1.5a), raising the 
possibility that ERH binding could block p21 interaction with Ciz1 or vice versa.  
1.2.4 Ciz1 may be involved in the DNA damage response 
Bioinformatic analysis has revealed a number of SQ/TQ motifs present in Ciz1’s amino 
acid sequence. These SQ/TQ motifs are simple two amino acid sequences made up of 
either a serine or a threonine residue followed by a glutamine residue, and are 
commonly phosphorylated by the PIKKs (Kim, Lim et al. 1999; O'Neill, Dwyer et al. 
2000). SQ/TQ motifs are often found in clusters and their presence is thought to be 
indicative of DNA damage response proteins (Traven and Heierhorst 2005). Their 
function as phosphorylation sites for ATM, ATR and DNA-PK was originally 
discovered in the DDR effector and tumour suppressor BRCA1, which contains 20 
motifs across its 1863 amino acids (Cortez, Wang et al. 1999). In comparison human 
Ciz1 contains 21 S/TQ motifs (Figure 1.5a), grouped in 3 main clusters across 898 
amino acids. This high incidence of potential phosphorylation sites raises the possibility 
that Ciz1 could be a substrate of ATM or ATR. If so, like many other genes involved in 
cell cycle control it may play a role in maintenance of the genome in addition to its role 
in promoting DNA synthesis. 
As mentioned in section 1.1.3, genes involved in the DNA damage response are 
frequently lost or mutated during carcinogenesis, and their disruption contributes to 
further deterioration of the genome. In recent years a number of observations have been 
made implicating Ciz1 as a player in tumour development, which are summarised 
below. 
1.2.4.1 Isoforms of Ciz1 are prevalent in diseased cells 
A survey of Ciz1 EST sequences found alternative splicing in approximately 11% of 
transcripts available on unigene in 2006, with spliced sites including exons 2, 4, 6 and 8 
(Rahman, Ainscough et al. 2007). Transcripts were derived from both healthy and 
diseased cells, with diseased samples displaying an increased frequency of alternate 
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splicing, and preferential skipping of exons 2, 4 and 6. Focused analysis of exon 4 has 
been undertaken in the Coverley lab (Rahman, Ainscough et al. 2007) and has shown 
that exon 4 is involved in Ciz1 nuclear foci formation, and that it is commonly 
mispliced in Ewing’s sarcoma family tumour cell lines as a direct consequence of 
mutation of intronic splicing regulators. Exon 4 deleted transcripts are also observed in 
non-diseased samples, particularly mouse embryonic stages, therefore exon 4 skipping 
could play a physiological role in normal cells, possibly during early developmental 
stages (Rahman, Ainscough et al. 2007). Differences in expression of the replication 
and anchor domains of Ciz1 have also been found in tumours. Transcription of exons in 
the C-terminus exceeded levels of N-terminal exon mRNA in a range of stage I through 
to III tumours, followed by an excess of the N-terminal replication domain once 
metastasis occurred (Sercombe et al, submitted). 
A Ciz1 splice variant lacking an eight amino acid sequence from exon 14 has been 
identified. This b-variant of Ciz1 has an altered sub-nuclear distribution (Higgins, 
Roper et al, submitted). B-variant is limited to tumour cells, and has so far been 
detected in neuroendocrine tumours, small cell lung cancers, non-small cell lung 
cancers, thyroid cancers and lymphomas. The b-variant protein is sufficiently stable that 
its exclusive expression by tumours is being exploited to develop a blood test with the 
goal of detecting early stage lung cancers. In initial tests b-variant was detected in as 
little as one microlitre of plasma in 37 out of 40 small cell and non-small cell lung 
cancer patients (Higgins et al, submitted). 
Lastly, a Ciz1 splice variant lacking exon 8 has also been found to be upregulated in a 
study of RNA isolated from the hippocampal region of brains of patients suffering from 
Alzheimer disease. While total Ciz1 showed no change in transcription compared to 
healthy tissue, expression of this exon 8 variant is increased 2.5-fold in the Alzheimer’s 
samples (Dahmcke, Buchmann-Moller et al. 2008). Recent years have seen speculation 
that dysregulation of the DNA damage response may contribute to neurodegenerative 
diseases such as Alzheimer’s, with BRCA1 known to be upregulated in neurofibrillary 
tangles, one of the classic lesion types symptomatic of the disease (Evans, Raina et al. 
2007; Staropoli 2008). Upregulation of this Ciz1 isoform could therefore potentially be 
representative of a similar loss of DDR function to that seen in tumours and tumour-
derived cell lines. 
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1.2.4.2 Matrix binding of Ciz1 is impaired in tumour-derived cell lines 
As previously described, the C-terminal region of Ciz1 mediates binding of the protein 
to the nuclear matrix (Ainscough, Rahman et al. 2007). Further study of Ciz1’s matrix 
binding properties also shows that it does not bind to the nuclear matrix in a range of 
tumour-derived cell lines. Immunofluorescence and Western blot experiments done in 
LnCap, SBC5, H727, RT4 and EJ cell lines showed that no Ciz1 was retained in the 
nucleus following treatment with DNase I, while HeLa-S3 cells showed a diminished 
level of matrix-bound Ciz1 [Munkley, unpublished]. These results mirror the behaviour 
of cyclin E in a panel of cancer and normal cell lines (Munkley, Copeland et al. 2010). 
This lack of matrix-binding may well reflect alternative splicing of Ciz1 in tumour-
derived cell lines impairing function of the anchor domain, similar to the changes in 
sub-nuclear localisation seen with the b-variant (Higgins et al, submitted). The 
correlation with cyclin E recruitment is being investigated, with particular focus on the 
order in which these two proteins are normally recruited to the nuclear matrix.  
1.2.4.3 Ciz1 is implicated in breast cancer 
There are two full and one partial estrogen response elements (ERE), to which the 
estrogen receptor α (ERα) is recruited, present between exons 1 and 2 of the Ciz1 gene 
and three partial EREs spread across the sequence downstream of exon 1 (Figure 1.5b). 
A region at the N-terminus of the Ciz1 protein interacts with the DNA-binding domain 
of ERα and co-localisation of the two proteins has been observed in the nuclear 
compartment (den Hollander, Rayala et al. 2006). Estrogen treatments of breast cancer 
cell lines were also shown to stimulate physical interactions between ERα and Ciz1 and 
to increase levels of Ciz1 mRNA. This increase does not occur in ERα negative cell 
lines, or in cells pre-treated with transcriptional inhibitors, but may not reflect the full 
extent of transcription as primers located in a region of exon 8 that is known to be 
alternatively spliced were used to detect Ciz1 mRNA (den Hollander, Rayala et al. 
2006).  
Ciz1 overexpression in breast cancer cell lines increased the growth rate over 6 days, 
and induced tumor formation in estrogen sensitive cells implanted into 
immunocompromised mice. This increase in cell proliferation was accompanied by 
increased levels of cyclin D1, an ERα-regulated gene, and could be inhibited by the 
addition of antiestrogenic agents (den Hollander, Rayala et al. 2006), and is notable for 
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its contrast with the effects of Ciz1 overexpression in healthy cell lines. In normal cells 
overexpression of Ciz1 triggers a block in the cell cycle, with an initial stimulation of 
DNA synthesis followed by an accumulation of cells in S phase [Sercombe, 
unpublished]. Conversely Ciz1-overexpressing breast cancer cell lines continued to 
replicate 6 days after transfection (den Hollander, Rayala et al. 2006).  
1.3 Aims 
This thesis seeks to investigate whether Ciz1 contributes to the response to DNA 
damage, using both traditional methods, such as immunofluorescence and real time 
PCR, and by modifying a cell free DNA replication system which has previously been 
used to study Ciz1’s role in DNA replication (Coverley, Marr et al. 2005). 
Initially, this thesis aims to adapt an existing cell-free system to permit use of nuclei and 
cytoplasmic extracts in which DNA damage signalling pathways have been activated. 
Furthermore it will show how immunofluorescence can be used to detect 
phosphorylated H2AX as a marker of DNA damage response activation in addition to 
the system’s original function of measuring DNA synthesis. By separating the nuclear 
and cytoplasmic components of the DDR and studying the effects of combining extracts 
treated with DNA damaging agents with untreated nuclei and vice versa, it is hoped that 
a clearer picture of the mechanisms of the DDR and the possible contribution of Ciz1 
can be gained. By exposing Ciz1 to damage-activated nuclei and cytosol, I aim to 
understand how Ciz1 fits in the DDR, to establish whether its SQ/TQ motifs are 
phosphorylated by the PIKKs, and to identify whether such modification takes place 
throughout the protein or is limited to certain regions. By tracking phosphorylation of 
the protein to specific functional domains, models for involvement of Ciz1 in the DDR 
can first be identified, and then tested with greater depth using more traditional 
methods.  
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2.1 Protein Analysis 
2.1.1 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Polyacrylamide gels were cast and run using the TTO slab electrophoresis system. 
Precision Plus All BlueTM protein standards were used. 6.5% resolving polyacrylamide 
gels were routinely used. An appropriate ratio of distilled water to 30% w/v acrylamide, 
0.8% bis-acrylamide (37.5:1) (National Diagnostics) was prepared. Tris-HCl pH8.8 was 
added to a final volume of 367mM, SDS to 0.1% w/v (Melford), ammonium 
persulphate (Sigma Aldrich) to 0.7% w/v and TEMED (Sigma Aldrich) to 1.3x10-3 v/v. 
5% stacking gels were routinely used. These were prepared in a similar manner to 
resolving gels, except that Tris-HCl pH6.8 was added to 125mM in place of Tris-HCl 
pH8.8 and TEMED to 2x10-3 v/v. 
2.1.2 Sample preparation for SDS-PAGE 
Protein extractions were generated by scrape harvesting cells in 4x SDS-PAGE loading 
buffer (3ml 1M Tris-HCl pH6.8, 6ml 100% glycerol, 1.6g SDS, 680µl β-
mercaptoethanol, 0.1% bromophenol blue). Purified protein on GST beads was 
resuspended in 4x SDS-PAGE loading buffer. Samples were boiled for 5 minutes, 
vortexed and boiled for a further 10 minutes to ensure complete denaturation. 
2.1.3 Western blotting 
2.1.3.1 Transfer 
A semi-dry blotter (Sigma Aldrich) was used to transfer proteins from polyacrylamide 
gels onto PROTRAN nitrocellulose transfer membrane (pore size 0.45µm, 
Whatman). The gel and membrane were sandwiched in between 8 pieces of 3mm 
chromatography paper (Whatman). All components were pre-soaked in semi-dry 
blotting buffer (297mM Tris-base, 10mM CAPS, 10% v/v methanol, 0.02% w/v SDS). 
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Table 2.1 Wash buffers for Western blot 
Buffer 
name 
Phosphate (PBS) or Tris 
(TBS) buffered saline 
% TWEEN-20 
(v/v) 
% Non-fat dried 
milk (w/v) BSA 
PBS PBS 0.01% 10% - 
TBS TBS 0.01% 5% - 
TBS BSA TBS 0.01% - 1mg/ml 
 
2.1.3.2 Antibody detection 
Western blots were blocked in the appropriate wash buffer with milk or BSA (Table 
2.1) prior to addition of primary antibodies (Table 2.2) in the same buffer for a 
minimum of 30 minutes. Membranes were then washed for 30 minutes in three changes 
of wash buffer with milk or BSA. Complementary secondary antibodies (Table 2.2) 
were applied in milk or BSA buffer for at least 30 minutes prior to three 10 minute 
rinses in wash buffer (without milk or BSA). Proteins were detected using ECLTM 
Western Blotting Detection Reagents and pre-flashed chemiluminescent Hyperfilm 
ECLTM (GE Healthcare). 
2.2 Cell culture 
2.2.1 Cell lines and culture conditions 
All media and supplements were obtained from Gibco (Invitrogen). All cell lines were 
grown in Dulbecco’s modified eagle medium with GLUTAMAXTM (DMEM) 
supplemented with 10% v/v foetal calf serum and 1x penicillin-streptomycin-glutamate. 
Cells were cultured in NunclonTMΔ dishes (NuncTM) and maintained at 37°C in a 
humidified atmosphere of 5% CO2. For S phase cell synchrony cells were also cultured 
in roller bottles (Corning) at 37°C and gassed once every 24 hours with 5% CO2 
balanced air through a 0.20µm syringe filter (Sartorius). 
Adherent cells were passaged by washing in Dulbecco’s phosphate buffered saline, 
without calcium, magnesium or phenol red (dPBS) and incubated with 0.05% v/v 
trypsin-EDTA at 37°C until cells were detached. Trypsin was quenched with 
supplemented DMEM. 
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2.2.2 Cell synchrony 
2.2.2.1 S phase synchrony 
HeLa-S3 cells were synchronised in S phase using thymidine (Sigma Aldrich). 2.5mM 
thymidine was added to DMEM for 24 hours. Cells were harvested for cell free 
components or subjected to immunofluorescence immediately following the 24 hour 
incubation  
2.2.2.2 G1 phase synchrony 
D3T3 cells were grown in 15cm2 dishes until confluent and released three days later. 
Cells were released by passaging and re-plating the equivalent of one 15cm2 plate onto 
four 15cm2 plates. Replated cells were grown for 17 hours after release before 
harvesting preparation of ‘replication competent’ late G1 phase nuclei (Coverley, Marr 
et al. 2005). 
2.2.3 DDR treatments 
2.2.3.1 Double strand break induction 
Induction of double strand DNA breaks was carried out by treating cells with etoposide 
(Sigma Aldrich). Etoposide was made up to a stock concentration of 42.5mM in DMSO 
(Sigma Aldrich) and stored at -20°C. DMEM was supplemented with 2µM or 20µM 
etoposide for a period of up to 24 hours. 
2.2.3.2 PIKK inhibition 
PIKK inhibition within cells was achieved by treatment with wortmannin (Sigma 
Aldrich). Wortmannin was made up to a stock concentration of 40mM in DMSO and 
stored at -20°C. DMEM was supplemented with 200µM wortmannin for 2 hours. 
2.2.4 Transfection of Ciz1/c-term/n-term 
GFP-C3 Ciz1, GFP-C3 Ciz1-C274, GFP-C3 Ciz1-N442 and pmax-GFP (Amaxa) were 
used for overexpression experiments. Constructs were transfected into cells using 
TransIT-3T3 (Mirus) or Amaxa Nucleofector Kit R (Amaxa). 
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2.2.4.1 Electroporation 
NIH3T3 cells were grown on 15cm2 plates and lifted using 0.05% v/v trypsin. Detached 
cells were quenched with DMEM and aliquoted into samples containing approximately 
2x106 cells. Cells were then collected by centrifugation at 200g for 10 minutes, and 
resuspended in 100µl of NucleofectorTM solution (Amaxa) prewarmed to room 
temperature. 5µg of construct to be transfected was added to the sample, which was 
then transferred into an Amaxa certified cuvette. An Amaxa Nucleofector TM was then 
used to transfect cells, using program T-30. Following electroporation, 500µl of DMEM 
pre-warmed to 37°C was added, and cells removed from cuvettes using plastic sterile 
pipettes (Amaxa). Cells were then plated onto 6 well plates or glass coverslips in 24 
well plates. 
2.2.4.2 Lipid transfections 
NIH3T3 cells were plated onto 6 well plates or glass coverslips in 24 well plates and 
transfected using the TransIT-3T3 transfection kit (Mirus Bio Corporation). 3.5µl 
TransIT-3T3 transfection reagent was incubated with 100µl Opti-MEM I reduced 
serum media (Invitrogen) for 15 minutes at room temperature. 3µl of the purified 
construct to be transfected was then added and incubated for a further 5 minutes at room 
temperature. Finally 1.5µl 3T3 Authority reagent was added and incubated for 15 
minutes at room temperature before adding to the cells. Transfection was allowed to 
continue for between 3 and 12 hours before TransIT reagents were replaced with fresh 
medium. 
2.3 Microscope analysis of cells 
2.3.1 Nuclear immunofluorescence 
Cells grown on glass coverslips were exposed to 0.05% Triton X-100 in 1xdPBS, and 
fixed with 4% paraformaldehyde.  Cells were washed three times in dPBS before being 
blocked for 20 minutes in antibody buffer (10 mg/ml BSA, 0.02% SDS, 0.1% Triton X-
100 in PBS). Cells were incubated in primary antibody at an appropriate concentration 
in antibody buffer (Table 2.2) for a minimum of 1 hour at 37°C. Cells were then washed 
three times in antibody buffer before incubation in a complementary secondary antibody 
at an appropriate concentration and 1/1000 Hoechst 33258 in antibody buffer for a 
minimum of 30 minutes. Cells were washed three more times in antibody buffer before 
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analysis by fluorescent microscopy.  Images were captured using Image Lab.  
fluorescent secondary antibodies Rabbit IgG F-0382 (Sigma) and alexa fluorescin-568 
mouse IgG A11031 (Molecular Probes). 
2.3.2 Nuclear matrix preparations 
Cells grown on glass coverslips were washed three times in dPBS, before a 5 minute 
incubation at room temperature in cytoskeletal buffer (CSK; 10mM Pipes, pH 6.8, 
300mM sucrose, 100mM NaCl, 1mM MgCl2, 1mM EGTA, 1mM DTT, 0.1mM ATP) 
supplemented with 0.05% Triton X-100. Cells were then washed three times in DNase 
buffer (20mM Tris-HCl, 50mM NaCl, 2mM CaCl2, 2mM MgCl2, 1mM DTT) before a 
30 minute incubation in DNase I (Roche) diluted 1:20 in the buffer provided. Cells were 
then washed twice in dPBS and fixed with 4% paraformaldehyde (PFA), before 
processing as described in 2.3.1.  
2.4 Gene expression analysis 
2.4.1 Total RNA extraction 
WI38 and U2OS cells were grown on 6 well plates. 1ml of TRIzol (Invitrogen) was 
added to each well and passed through a pipette several times before transfer to a 1.5ml 
eppendorf. After a 5 minute incubation at room temperature, 200µl chloroform was 
added and the sample shaken vigorously for 15 seconds, before a further 5 minute 
incubation. The aqueous phase was then isolated by centrifugation for 15 minutes at 
12000g and 4°C, and transferred to a fresh eppendorf. 0.5ml isopropanol was added, 
and a further 15 minute incubation at room temperature carried out. RNA was then 
pelleted by centrifugation for 10 minutes at 12000g and 4°C, and the supernatant 
discarded. The RNA pellet was washed in 1ml of 75% ethanol and vortexed before 
centrifuging for 5 minutes at 7500g and 4°C. Ethanol was then removed from the pellet, 
which was allowed to air dry before resuspension in 20µl nuclease-free water at 55°C 
for 10 minutes. Total RNA was stored at -20°C. 
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Table 2.3 Primers and probes 
Name 
Primer or  
probe Sequence 
5' reporter/  
3' quencher 
hCIZ1 EXON6 F Primer TGCCTGTGGAAGACAAGTCA n/a 
hCIZ1 EXON 7 R3 Primer TGCTGGAGTGCGTTTTTCCT n/a 
EX14F Primer CGAGGGTGATGAAGAAGAGGA n/a 
EX16R Primer CCCCTGAGTTGCTGTGATA n/a 
Hs ActB-F Primer GGTCATCACCATTGGCAATG n/a 
Hs ActB-R Primer CGTCACACTTCATGATGGAGTTG n/a 
Exon 7 Joe probe Probe CCCTGCCCAGAGGACATCGCC 
Joe/Blackhole 
quencher 1 
New ex16 probe Probe CACGGGCACCAGGAAGTCCA Fam/Tamra 
Hs ActinB Probe ATGGAGTCCTGTGGCATCCACGAAACTAC Fam/Tamra 
AQ1FWD Primer AGGCCAGCAGCAGCGCCCAGCAGGAGTTCC n/a 
AQ1REV Primer GGAACTCCTGCTGGGCGCTGCTGCTGGCCT n/a 
AQ2FWD Primer CAACACTCGGCCCAGACCTGCCTGCTGTCC n/a 
AQ2REV Primer GGACAGCAGGCAGGTCTGGGCCGAGTGTTG n/a 
AQ3FWD Primer ATCCAGCACCGTAGGGCACAGGAGCACAAG n/a 
AQ3REV Primer CTTGTGCTCCTGTGCCCTACGGTGCTGGAT n/a 
AQ4FWD Primer GTGGAGCACGTGAAGGCCCAGGGACACAAG n/a 
AQ4REV Primer CTTGTGTCCCTGGGCCTTCACGTGCTCCAC n/a 
pGEXFor Primer GGGCTGGCAAGCCACGTTTGGTG n/a 
pGEXRev Primer CCGGGAGCTGCATGTGTCAGAGG n/a 
 
2.4.2 Reverse transcription 
1µg of total RNA in 10µl nuclease-free water was incubated with 1µl 10mM dNTP 
(dGTP, dATP, dCTP, dTTP; Invitrogen) and 1µl 500µg/ml random primers (Promega). 
Samples were incubated at 65°C for 10 minutes in a PTC-200 Peltier Thermal Cycler 
(MJ Research). Reactions were then incubated on ice for 5 minutes. 1x M-MLV 5x 
reaction buffer, 0.01M DTT and 10U/µl M-MLV reverse transcriptase (Promega) were 
added to all reactions to give a final volume of 20µl. Reactions were incubated at 42°C 
for 52 minutes followed by 70°C for 15 minutes. cDNA was stored at  -20°C. 
2.4.3 Real time PCR 
Primers and TaqMan probes (Sigma Aldrich) for actin and for Ciz1 exons 7 and 16 
were kindly supplied by Dr Gillian Higgins (Table 2.3).  
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Reactions were carried out in MicroAmpTM optical 96-well reaction plates with optical 
adhesive film (Applied Biosystems) in a total volume of 25µl. 50ng cDNA was 
incubated in 1x TaqMan PCR mix, 0.4µM forward primer, 0.4µM reverse primer and 
0.4µM probe. Samples were run on the ABI Prism 7000 Sequence Detection system 
using the relative quantification assay. The standard protocol for 25µl reaction volumes 
was used (50°C [2 minutes], 95°C [10 minutes], followed by 40 cycles of 95°C [15 
seconds], 60°C [1 minute]). The threshold level of fluorescence was detected 
automatically by the ABI Prism software. The cycle number at which the sample passed 
the threshold level is the Ct value. To control for variation in sample recovery both exon 
primer pairs were normalised to the housekeeping gene actin by subtracting the actin Ct 
value from the exon Ct value for each sample (∆Ct). The zero hour time point sample 
for exon 7 was selected as a calibrator sample and all other exon 7 and 16 expression 
values were expressed relative to it. 
2.5 DNA manipulation and bacterial transformation 
2.5.1 Glycerol stocks 
Glycerol stocks or single colonies from agar plates were used to inoculate 6ml LB broth 
(Merck Biosciences) in 12ml round bottom culture tubes supplemented with 100µg/ml 
ampicillin. Cultures were grown overnight at 37°C and 200rpm on a shaker. Glycerol 
stocks were prepared by mixing 0.7ml of bacterial culture with 0.3ml sterile glycerol 
and stored at -80°C. 
2.5.2 Plasmid purification 
Overnight bacterial cultures were harvested by centrifugation at 3000g for 12 minutes. 
Plasmid DNA was purified using the QIAprep spin mini-prep kit (Qiagen) according 
to manufacturer’s instructions. Purified DNA was stored at -20°C.  
2.5.3 Preparation of chemically competent E. coli 
Chemically competent BL21(pLys) cells were prepared by streaking cells from glycerol 
stocks onto LB agar with 34µg/ml chloramphenicol and incubating overnight at 37°C. 
A single colony was used to inoculate 6ml LB broth and cultured overnight as described 
in 2.7.1. 50ml LB broth was inoculated with 0.5ml overnight culture and allowed to 
grow at 37°C on a shaker until the OD550 reached 0.6. The cells were harvested by 10 
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minutes centrifugation at 2000g and 4°C, and resuspended in 20ml ice cold buffer 
(10mM Tris-HCl pH8.0, 50mM CaCl2). Cells were incubated on ice for 20 minutes and 
then harvested by 10 minutes centrifugation at 2000g and 4°C. The cell pellet was 
resuspended in 2ml freeze/thaw buffer (10mM Tris-HCl pH8, 100mM CaCl2, 15% v/v 
glycerol), and stored as 100µl aliquots at -80°C. 
2.5.4 Transformations 
Competent E. coli cells were thawed on ice and incubated with 1-3µl plasmid DNA for 
20 minutes on ice. Cells were heat-shocked at 42°C for 45 seconds and incubated on ice 
for 2 minutes. Cells were resuspended in 300µl S.O.C medium (Invitrogen) and 
incubated at 37°C on a shaker at 200rpm for 90 minutes. Cells were then plated onto LB 
agar containing 100µg/ml ampicillin and incubated overnight at 37°C. 
2.5.5 Site directed mutagenesis 
Sequential ECiz1 alanine substitution mutations of the S/TQ at S411, S435 and T480 
were generated so that the three SQ/TQ motifs were changed to AQ. Mutagenesis was 
performed using the Stratagene QuikChange method, following the manufacturer’s 
instructions, using pGEX-ECiz1 as template, and custom primers synthesized by Sigma 
Aldrich (Table 2.3).  
2.5.5.1 Sequencing 
ECiz1 AQ1-3 in pGEX-6P-3 was sequenced using the pGEXFor and pGEXRev primers 
(Table 2.3). Sequencing was carried out in house by the Technology Facility at the 
University of York, using the Applied Biosystems 3130. 
2.6 Protein expression and purification from bacteria 
Full length ECiz1, ECiz1 AQ1-3 (Section 2.5.5), ECiz1 N442 and ECiz1 C274 
(Coverley, Marr et al. 2005) were expressed as GST-fusions in pGEX-6P-3 and purified 
by sonication for use in SQ/TQ phosphorylation assays. All LB broth cultures were 
supplemented with 100µg/ml ampicillin and 34µg/ml chloramphenicol. 
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2.6.1 Manual induction of expression 
Glycerol stocks were used to inoculate 75ml LB broth cultures which were grown at 
37°C overnight on a shaker at 200rpm. Overnight cultures were used to inoculate 750ml 
cultures of LB broth. Cultures were grown at 20°C on a shaker at 160rpm and induced 
to express with 100µM isopropyl-β-D-thiogalactopyranoside at OD600 0.6-0.8 and then 
cultured for a further 20 hours.  
Cells were collected by 12 minutes centrifugation at 4500rpm and 4°C in a Sorvall 
Evolution centrifuge, resuspended in PBS and divided into two or more equal aliquots. 
Aliquots were spun down for 15 minutes at 3000rpm and 4°C, and the supernatant 
discarded. Pellets were flash frozen in liquid nitrogen and stored at -80°C. 
2.6.2 Autoinduction of expression 
Glycerol stocks were used to inoculate 75ml LB broth cultures which were grown at 
37°C overnight on a shaker at 200rpm. Overnight cultures were used to inoculate 750ml 
cultures of autoinducing medium. Autoinducing medium was prepared by 
supplementing NZY medium (750ml NZY medium [Fisher], 7.5g tryptone, 3.75g yeast 
extract) with 1mM MgSO4, 50µM Fe, 20µM Ca, 10µM Mn, 10µM Zn, 2µM Co, 2µM 
Cu, 2µM Ni, 2µM Mo, 2µM Se, 2µM H3BO3, 25µM (NH4)2SO4, 50µM KH2PO4, 50µM 
Na2HPO4 and 360.31mM α-Lactose monohydrate. Cultures were grown at 20°C on a 
shaker at 200rpm for 24 hours. 
Cells were harvested and frozen as described in Section 2.6.1. 
2.6.3 Sonication 
Pelleted cells were thawed in 12.5ml resuspension buffer (50mM HEPES pH7.8, 
135mM NaCl, 3mM EDTA, 1:10000 monothioglycerol, 1mM PMSF, 0.1mg/ml 
lysozyme, 1 Roche complete protease inhibitor tablet/25ml of buffer). The suspension 
was sonicated on ice for 3 minutes at 50% power using a Bandelin sonicator (Bandelin, 
Berlin, Germany). Samples were then cleared through centrifugation for 30 minutes at 
20,000rpm and 4°C in a Sorvall Evolution centrifuge.  
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2.6.4 GST binding 
375µl GST beads (GE Healthcare) were resuspended in 25ml HEPES buffered saline 
(50mM HEPES pH7.8, 135mM NaCl, 3mM EDTA, 1:10000 monothioglycerol) and 
incubated on a shaker for 1 hour at room temperature. Beads were then collected by 
centrifugation at 1000rpm for 1 minute. The lysate collected in Section 2.6.3 was added 
to GST beads, and incubated on a wheel for 1 hour at 4°C. Supernatant was removed by 
centrifugation for 10 minutes at 1000rpm and 4°C, then beads were resuspended in 5ml 
wash buffer (50mM HEPES pH7.8, 135mM NaCl, 3mM EDTA, 1:10000 
monothioglycerol, 1 Roche complete protease inhibitor tablet/50ml) and transferred to a 
fresh tube. The original tube was washed with a further 5ml of wash buffer, which was 
then added to the transferred beads. Beads were then incubated on a wheel for 5 minutes 
at 4°C, before this centrifugation and resuspension step was repeated a further 5 times. 
2.7 Cell free system 
2.7.1 Harvesting of S phase nuclei and extracts 
HeLa S3 cells in the process of S phase synchrony were treated with etoposide at the 
indicated concentration for a period of up to 3 hours, to coincide with the final 3 hours 
of thymidine-induced synchronisation. Cells were harvested from suspension culture by 
centrifugation for 10 minutes at 1000rpm at 4°C under minimal lighting, washed in ice 
cold PBS and in ice-cold hypotonic buffer (20mM K-HEPES pH 7.8, 5mM potassium 
acetate, 0.5mM MgCl, 0.5mM DTT). After centrifugation for 10 minutes at 1500rpm at 
4°C cell pellets were resuspended in an equal volume of hypotonic buffer and disrupted 
using a Dounce Homogeniser. Nuclei were pelleted by centrifugation at 3000rpm for 10 
minutes. The supernatant “soluble extract” fraction was removed and immediately 
frozen as 50µl beads in liquid nitrogen. The pellet fraction containing nuclei was 
resuspended in an equal volume of hypotonic buffer, snap frozen in 5µl aliquots and 
stored in liquid nitrogen. 
2.7.2 Harvesting of G1 nuclei 
Late G1 synchronised D3T3 nuclei on 15cm2 plates were washed twice in ice cold PBS 
and once in ice-cold hypotonic buffer, before a ten minute incubation in hypotonic 
buffer at 4°C. Plates were then drained before scrape harvesting cells at 4°C. Harvested 
cells were disrupted using a Dounce Homogeniser and nuclei were pelleted by 
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centrifugation at 3000rpm for 10 minutes. The supernatant “soluble extract” fraction 
was removed before the pellet fraction containing nuclei was resuspended in an equal 
volume of hypotonic buffer. Nuclei were snap frozen in 5µl aliquots and stored in liquid 
nitrogen. 
2.7.3 DNA replication elongation assay  
Replication elongation assays were carried out in S phase cytosolic extract 
supplemented with 1:10 premix, 1:50 CPK, and 1:75 MgCl2 (to final concentrations of 
40mM K–HEPES pH 7.8; 7mM MgCl2; 3mM ATP; 0.1mM each of GTP, CTP, UTP; 
0.1mM each of dATP, dGTP, and dCTP; 0.5mM DTT; 40mM phosphocreatine and 
40mM creatine phosphokinase). Nuclei (~1x104/µl) and supplemented extracts were 
incubated together for up to 30 minutes at 37°C. Typically, 10µl of extract was 
combined with 1.5µl nuclei. 1nM biotin-16-dUTP (Roche) was added to reactions either 
at the start or after 5 minutes, as indicated, and was incorporated into newly synthesised 
DNA.  
To visualise DNA synthesis, cell free reactions were quenched by addition of 50µl 0.2% 
Triton X-100 in PBS, followed by 50µl 8% PFA, before transfer of nuclei onto 
polylysine-coated coverslips by centrifugation through a 20% sucrose cushion. 
Incorporation of biotinylated-nucleotides was detected with streptavidin-FITC 
(Amersham) diluted 1/500 in antibody buffer for 1 hour at 37°C, before visualisation by 
fluorescent microscopy. Cells were probed for γH2AX using monoclonal antibody 05-
636 (Upstate) diluted 1/2000 in antibody buffer for 1 hour at 37°C. Alexa 568 goat anti-
mouse secondary antibody (Molecular Probes) was used diluted 1/1000 in antibody 
buffer for 1 hour at 37°C. DNA was counterstained by inclusion of 1/1000 Hoechst 
33258 in the secondary antibody step. For combined detection of γH2AX and DNA 
synthesis, nuclei were probed for phosphorylated H2AX as described above, with 
inclusion of streptavidin-FITC in both primary and secondary antibody steps.  Hoechst, 
Alexa 568 and streptavidin-FITC were visualised using Zeiss filter sets 10, 15 and 2 
respectively. 
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2.7.3.1 Inhibition of PIKKs 
To inhibit PIKKs, supplemented cell free extracts were incubated with 200µM 
wortmannin (Sigma-Aldrich) or 200µM LY294002 (Sigma-Aldrich) for ten minutes at 
4°C prior to addition of nuclei. 
2.7.3.2 Pre-conditioning of extracts 
For “preconditioning” experiments, 20µl supplemented naive extract was incubated for 
10 minutes at 37°C with ~2x105 nuclei. Reactions were then centrifuged at 3000rpm to 
pellet nuclei and 10µl extract was removed and applied to fresh nuclei.  
2.7.3.3 Inhibition of DNA synthesis 
To inhibit DNA synthesis, supplemented cell free extracts were incubated with 1mM 
aphidicolin (Sigma-Aldrich) for ten minutes at 4°C prior to addition of nuclei. 
2.7.3.4 Ciz1 titration 
To titrate Ciz1 into cell free reactions, supplemented cell free extracts were incubated 
with purified Ciz1 protein at the indicated concentration for ten minutes at 4°C prior to 
addition of nuclei. 
2.7.4 Initiation assay 
Replication elongation assays were carried out in supplemented S phase cytosolic 
extracts. Nuclei (~1x104/µl) and supplemented extracts were incubated together for 30 
minutes at 37°C. Typically, 10µl of extract was combined with 1µl nuclei. 1nM biotin-
16-dUTP (BdUTP; Roche) was added to reactions after 5 minutes. To visualise DNA 
synthesis, cell free reactions were quenched by addition of 50µl 0.2% Triton X-100 in 
PBS, followed by 50µl 8% PFA, before transfer of nuclei onto polylysine-coated 
coverslips by centrifugation through a 20% sucrose cushion. Incorporation of 
biotinylated-nucleotides was detected with streptavidin-FITC (Amersham) diluted 1/500 
in antibody buffer for 1 hour at 37°C, before visualisation by fluorescent microscopy. 
Nuclei from late G1 populations that were induced to initiate DNA replication in vitro 
in the presence of S phase extract were scored by eye at 600x magnification. All nuclei 
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with focal staining were scored as positives regardless of the extent of nucleotide 
incorporation.  
2.7.5 Imaging and quantification 
Coverslips were mounted using Vectashield mounting medium (Vector Labs) to prevent 
fading of fluorescence. Hoechst, FITC (newly synthesized DNA) and Alexa 568 
(phosphorylated H2AX) fluorescence were photographed at 600x magnification with an 
Axiovert microscope fitted with an AxioCam camera (Carl Zeiss Vision, Hallbergmoos, 
Germany) using a 63/1.40 oil immersion objective and constant exposure parameters 
(FITC: 700mS; Alexa 568: 50mS). The average fluorescence intensity within the largest 
rectangular area of individual nuclei was measured using Openlab software 
(Improvision, Coventry, UK). The mean pixel intensity within the selected areas were 
collected for 28-110 nuclei per reaction prior to any image manipulation, and displayed 
in histograms along with standard error of the mean (SEM) calculated using Excel. 
Probability values were calculated using the “t-test: paired two-sample for means” and 
“t-test: two sample assuming unequal variances” tools in Excel’s data analysis package. 
Example images shown alongside histograms were adjusted using Adobe Photoshop to 
increase image intensity for reproduction. In all cases, control and test samples were 
treated identically.  
2.7.6 Protein phosphorylation assays 
GST-tagged ECiz1, ECiz1-AQ1-3, ECiz1-N442 and ECiz1-C274 bound to GST-beads 
were incubated in supplemented S phase cytosolic extracts for 30 minutes at 37ºC, 
before being removed by centrifugation and washed once with PBS.  4x SDS PAGE 
loading buffer was then added to denature the protein.  Samples were then run on a 
6.5% SDS-PAGE gel, transferred to nitro-cellulose paper, and probed for antibodies as 
described.  Western blots were developed using enhanced chemiluminescence and 
Amersham preflashed chemiluminescence film.  Antibodies used were Ciz1 1793, GST 
and phospho-(Ser/Thr) ATM/ATR substrate 2851S (Cell signalling) (Table 2.2). 
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Chapter 3 
THE CELL FREE SYSTEM AS A TOOL TO STUDY THE 
DNA DAMAGE RESPONSE 
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3.1 Introduction 
Cell free DNA replication systems were originally developed using viral control 
elements (Stillman 1989) and later, activated Xenopus egg extracts (Murray and 
Kirschner 1989). These allowed study of enzymatic and structural features of DNA 
replication, but did not permit study of the regulatory events of the somatic cell cycle. 
More suitable for this purpose is a system derived from mammalian cells, that supports 
the replication initiation process using cytosolic extracts and intact isolated nuclei from 
synchronised cells (Krude, Jackman et al. 1997; Coverley, Laman et al. 2002). This 
chapter details the adaptation of a mammalian cell-free DNA replication system for 
reconstitution and analysis of the DNA damage response (DDR). 
3.2 Aims 
This chapter aimed to develop a cell-free system as a tool with which to study the DDR. 
Goals were: 
• To identify and optimise conditions for production of isolated nuclei and cell 
extract from cells undergoing the DDR. 
• To combine an existing BdUTP assay with immunofluorescence techniques to 
allow DNA replication initiation and elongation to be visualised in concert with 
markers of the DDR. 
• To investigate whether different steps of the DDR could be reconstituted in vitro 
at multiple stages of the cell cycle. 
• To characterise the properties of isolated nuclei and cytosolic extracts in which 
DDR signalling had been activated. 
• To establish whether the presence of physical DNA damage is necessary for 
activation of the DDR in nuclei. 
3.3 Experimental design 
The topoisomerase II inhibitor, etoposide, was used to induce double strand breaks in 
thymidine-synchronised S phase HeLa cells, generating populations of “damaged 
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nuclei” and “damage-activated extracts” for cell-free experiments. Eukaryotic 
topoisomerase II catalyses the conformational and topological changes in DNA 
necessary for DNA replication, allowing formation of a junction between two sections 
of doublestranded DNA via the formation of transient double strand break.  Etoposide 
functions by stabilising the topoisomerase II cleavable complex, stalling the replication 
fork and preventing these temporary breaks from being annealed (Chen and Liu 1994; 
Li and Liu 2001), and was chosen because it could be easily incorporated into existing 
methods for harvesting nuclei and extracts, unlike ionising radiation. Etoposide also 
chiefly induces double strand breaks during the S phase of the cell cycle, which could 
be a drawback if studying cycling cells, but proved compatible with the thymidine 
synchronisation used here.  
Damaged nuclei and damage-activated extracts were combined with “naive” nuclei and 
extracts from untreated cells to reconstitute distinct steps in the DDR. After incubation 
in extract supplemented with nucleotide, cofactors and an energy regenerating system 
the extent of DNA synthesis and H2AX phosphorylation were monitored in nuclei by 
fluorescent microscopy. Incorporation of biotinylated nucleotide allowed quantification 
of the extent of DNA synthesis, while phosphorylated H2AX was detected with a well-
characterised phosphorylation sensitive monoclonal antibody. 
3.4 Results 
3.4.1 Optimisation of harvesting and labelling methods 
The cell-free system that was adapted to produce the data in this chapter has previously 
been used by the Coverley laboratory for both DNA replication initiation and elongation 
studies. In order to adapt the system to permit study of DDR activation and signalling, a 
number of developments were required.  
3.4.1.1 Suitability of thymidine as a synchronisation method for DDR studies 
The cell-free system involves the use of thymidine to synchronise cells in S phase 
before harvesting nuclei and cytosolic extract. Existing protocols treat cells for 24 hours 
with thymidine, prior to a 24 hour release and a second 24 hour treatment before 
harvesting. Thymidine inhibits replication by depleting cellular pools of dCTP, slowing 
progression of replication forks (Bjursell and Reichard 1973). Recovery of replication 
forks from this block has been shown to occur by a homologous recombination repair 
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mediated mechanism (Bolderson, Scorah et al. 2004). This process is dependent on both 
ATM and ATR, a fact which has not been a concern when using the system solely to 
measure DNA replication elongation, but which could potentially affect the outcome of 
studies examining DDR induction.  
In order to establish whether thymidine treatment was a suitable method of cell 
synchronisation for these studies, intact S3 HeLa cells were cultured for 24 hours in 
either 2.5mM thymidine, 20µM etoposide, or both thymidine and etoposide, before two 
γH2AX antibodies, a mouse monoclonal and a rabbit polyclonal, were used to visualise 
phosphorylated H2AX by immunofluorescence. The rabbit polyclonal displayed no 
difference between treated and control cells, and was not used for further experiments.  
Using the mouse monoclonal antibody, cells treated with thymidine displayed an 
increase in H2AX phosphorylation but levels were distinctly lower than in either the 
etoposide or etoposide & thymidine-treated populations (Figure 3.1a). Additionally a 
timecourse was carried out during which total protein was harvested from S3 HeLa cells 
up to 5 hours after release from a 24 hour treatment with 2.5mM thymidine. Protein was 
then analysed by Western blot for presence of phosphorylated H2AX. γH2AX could not 
be seen in thymidine treated samples, but was apparent in a control population treated 
with 20µM etoposide for 2 hours (Figure 3.1b). Subsequently, a single thymidine 
release was used for preparation of all nuclei and extracts rather than the double 
synchronisation recommended by the laboratory protocol.  
3.4.1.2 Harvesting of nuclei - effect of increasing roughness of Dounce homogenisation 
As part of the harvesting protocol for the cell-free system, cells are swollen using a 
hypotonic buffer, before being lysed by Dounce homogenisation to separate nuclei from 
cytosolic extract. To investigate whether the physical stress of homogenisation had the 
potential to induce DNA lesions, S3 HeLa cells synchronised in S phase were divided 
into three samples with an increasing number of strokes used to lyse each sample. 
Immunofluorescence was then used to visualise the base level of H2AX 
phosphorylation in each population of nuclei.  
Nuclei from cells lysed using either ten or twenty strokes displayed equivalent, low 
levels of H2AX phosphorylation in approximately half the population, while nuclei 
from cells lysed using thirty strokes showed a distinct increase in both the proportion  
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undergoing phosphorylation, and the levels of phosphorylation induced in those nuclei 
(Figure 3.2). Nuclei were subsequently harvested using ten to fifteen strokes and 
cytosolic extracts using between twenty and twenty-five strokes, with lysis being 
visually confirmed by microscopy. 
3.4.1.3 Optimisation of BdUTP assay 
The initial question asked with this cell free system was whether damaged nuclei 
incubated in naive cytosolic extract and allowed to undergo DNA synthesis would 
display a decrease in BdUTP incorporation compared to healthy nuclei in the same 
conditions. This would serve as a proof of concept to demonstrate that DNA damage 
signalling was being reconstituted in the system. As expected, a decrease in 
incorporation of the fluorescently labelled nucleotide biotinylated-UTP (BdUTP) to 
DNA was observed in the damaged population of nuclei (Figures 3.3a and 3.3b). The 
question then arose of whether the system could be optimised to increase this 
differential. 
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Figure 3.3  Damaged nuclei recapitulate the DNA damage response in a cell-free 
environment 
a) Images of sites of DNA replication in naïve and damaged S phase HeLa-S3 nuclei  
incubated in naïve S phase HeLa-S3 extract and supplemented with BdUTP at either 
the start of the reaction or after 5 minutes. Reactions were processed as described in 
the methods (Section 2.7). BdUTP incorporation was visualised using streptavidin-
fluorescein (green) and fluorescent microscopy. Nuclei were counterstained with 
Hoechst 33258 (blue). 
b) Quantification of BdUTP incorporated into nuclear DNA in cell-free reactions in 
which naïve (light blue) or damaged (dark blue) nuclei are incubated with naïve 
extract, and BdUTP is added at either the start of the reaction or after 5 minutes. 
Histogram shows average fluorescent intensity with standard error of the mean and is 
representative data from one of two experiments. Asterisks represent the p-value 
found by t-test assuming unequal variances:  = 0.05>p>0.01;  = 0.01>p>0.001;                
 p<0.001. n = number of nuclei quantified per sample.  
c) Fluorescent images of sites of DNA replication and phosphorylated H2AX in 
naïve and damaged S phase HeLa-S3 nuclei  incubated in naïve S phase HeLa-S3 
extract. Reactions were processed as described in the methods (Section 2.7). BdUTP 
incorporation was visualised using streptavidin-fluorescein (green) and H2AX 
phosphorylation with mouse monoclonal anti-phospho H2AX (Ser139) antibody, and 
anti-mouse Alexa 568 conjugated secondary antibody.  Nuclei were counterstained 
with Hoechst 33258 (blue). 
d)  Quantification of BdUTP incorporated into nuclear DNA (blue)  and H2AX 
phosphorylation (red) in cell-free reactions in which naïve and damaged nuclei are 
incubated in naïve extract. Histogram shows average fluorescent intensity with 
standard error of the mean and is representative data from one of five experiments. 
Asterisks represent the p-value found by t-test assuming unequal variances:              
 = 0.05>p>0.01;  = 0.01>p>0.001;  p<0.001. n = number of nuclei 
quantified per sample.  
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The presence of double strand breaks provides a physical barrier to DNA replication 
elongation in vivo, in addition to halting the cell cycle via the DDR. Using template 
nuclei that have been severely damaged and contain many double strand breaks, this 
might be expected to be a major source of replication fork restraint. In order to 
maximise detection of the effect of this damage on DNA synthesis in vitro, the effect of 
delaying addition of BdUTP to cell free reactions, allowing active replication forks to 
encounter damaged sites before labelling commenced, was investigated.  
Naive and damaged nuclei were either incubated in naive extract supplemented with 
BdUTP for 30 minutes, or allowed a 5 minute preincubation in naive extract prior to 
addition of BdUTP, followed by a 25 minute incubation. In both instances BdUTP 
incorporation was lower in damaged nuclei compared to naive nuclei, but the difference 
was significantly more marked in reactions that had received the preincubation (Figures 
3.3a and 3.3b). A 5 minute preincubation has since been used in all cell-free 
experiments.  
3.4.1.4 Simultaneous detection of both phosphorylated H2AX and BdUTP incorporation  
Having confirmed that the DDR could be reconstituted in vitro, the next step was to add 
a second marker into the system, allowing direct visualisation of DDR signalling, rather 
than relying solely on the indirect measure of damage provided by levels of DNA 
synthesis. To achieve this, the processing protocol for the assay was altered to allow 
incubation of nuclei immobilised on coverslips in the γH2AX mouse monoclonal 
antibody and a complementary secondary antibody concurrent with staining of BdUTP 
with streptavidin-FITC. To maximise detection of BdUTP a short incubation of 1 hour 
was used for primary and secondary antibodies, with streptavidin-FITC being included 
in both steps. Using this method both BdUTP and phosphorylated H2AX could be 
clearly visualised in nuclei. As expected the level of phosphorylated H2AX was 
significantly greater in damaged nuclei compared to naive nuclei, reflecting the 
presence of etoposide induced double strand breaks (Figures 3.3c and 3.3d). 
3.4.2 Extracts from etoposide-treated cells induce the DDR in the absence of 
physical damage 
The proof of concept and optimization experiments described so far demonstrate that 
inhibition of DNA replication and induction of H2AX phosphorylation are stable in 
vitro even when soluble signalling molecules in the naive extracts used are initially 
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inactive. It seems likely that the presence of DSBs in damaged nuclei activates soluble 
cytosolic factors in these extracts as it would in an intact cell, allowing propagation of 
damage signalling. To ask whether this soluble damage signalling and its impact on 
nuclear functions such as DNA replication can be uncoupled from the damage itself, the 
effect of damage-activated extract on naive nuclei was examined.  
Exposure of naive nuclei to activated extract suppressed DNA replication elongation 
compared to extract from untreated cells, confirming the presence of soluble signalling 
molecules able to inhibit DNA replication in vitro in damage-activated extract. 
Furthermore this was accompanied by phosphorylation of H2AX in naive nuclei 
(Figures 3.4a and 3.4b), showing that the presence of physical damage is not required 
for the early stages of DDR signalling to be activated.  
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Figure 3.4  Damage-activated extract activates the DNA damage response in 
naïve nuclei 
a) Fluorescent images of sites of DNA replication and phosphorylated H2AX in 
naïve S phase HeLa-S3 nuclei incubated in naïve and damage-activated S phase 
HeLa-S3 extract. Reactions were processed as described in the methods (Section 
2.7). BdUTP incorporation was visualised using streptavidin-fluorescein (green) and 
H2AX phosphorylation with mouse monoclonal anti-phospho H2AX (Ser139) 
antibody, and anti-mouse Alexa 568 conjugated secondary antibody.  Nuclei were 
counterstained with Hoechst 33258 (blue). 
b) Quantification of BdUTP incorporated into nuclear DNA (blue)  and H2AX 
phosphorylation (red) in cell-free reactions in which naïve nuclei are incubated in 
naïve and damage-activated extract. Histogram shows average fluorescent intensity 
with standard error of the mean and is representative data from one of five 
experiments. Asterisks represent the p-value found by t-test assuming unequal 
variances:  = 0.05>p>0.01;  = 0.01>p>0.001;  p<0.001. n = number of 
nuclei quantified per sample.  
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When this experiment was extended to monitor the effect on initiation of DNA 
replication rather than elongation from pre-initiation replicons, a significant effect was 
also recorded. Using synchronized replication competent G1 phase nuclei, activated 
extract inhibited initiation of DNA replication by up to 49% compared to naive extract 
(Table 3.1). Incubation in activated extract resulted in consistent lower levels of 
initiation across multiple batches of G1 nuclei compared to naive extract.  
3.4.3 Contrasting effects of the PIKK inhibitors wortmannin & LY294002 upon 
H2AX phosphorylation 
The cellular response to double strand breaks is dependent upon and mediated by the 
PIKKs, ATM, ATR and DNA-PK. To ask whether the PIKKs are required in vitro for 
damage-activated extract to induce H2AX phosphorylation and restraint of DNA 
replication, a pair of well-characterised PIKK inhibitors was used. Activated extracts 
were supplemented with these inhibitors prior to incubation with naive nuclei so that 
both extract and nuclei-derived kinases would be silenced. 
3.4.3.1 Inhibition of DNA replication and H2AX phosphorylation by activated extract is 
PIKK-dependent 
Wortmannin is an irreversible inhibitor of the PIKKs which modifies protein structure 
by covalently binding to kinases (Norman, Shih et al. 1996). In the presence of 200µM 
wortmannin, a concentration known to affect all PIKKs (Rodriguez-Bravo, Guaita-
Esteruelas et al. 2006), H2AX phosphorylation was dramatically inhibited in naive 
nuclei (Figure 3.5). In addition, nuclei displayed on average a 46% increase in BdUTP  
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incorporation indicating that DDR-mediated restraint of DNA synthesis was blocked 
(Table 3.2). LY294002 is a competitive and reversible inhibitor of the PIKKs (Vlahos, 
Matter et al. 1994). When damage-activated extract was supplemented with either 
50µM or 200µM LY294002, BdUTP incorporation in naive nuclei increased by an 
average of 10% and 52% respectively, however at both concentrations H2AX 
phosphorylation rose by over 30% (Figure 3.5a; Table 3.2).  
3.4.3.2 PIKK inhibitors stimulate DNA replication elongation in naive nuclei & extracts 
Naive nuclei were also incubated in naive extract supplemented with either 200µM 
wortmannin or 200µM LY294002. Under these circumstances both inhibitors 
stimulated BdUTP incorporation above levels observed in naive nuclei incubated in 
naive extract alone (Table 3.3), but only wortmannin abolished base levels of H2AX 
phosphorylation (Figure 3.6). Only a single replicate was carried out using LY294002, 
but a contrasting effect upon H2AX phosphorylation was seen compared to naive  
Condition Concentration Marker 
Mean untreated 
pixel intensity 
Sample 
size 
Mean treated 
pixel intensity 
Sample 
size 
Percentage 
change 
naive/activated 200uM Wortmannin BdUTP 709.55  44 1141.79 56 60.92% 
naive/activated 200uM Wortmannin BdUTP 982.75 46 1107.48 52 12.69% 
naive/activated 200uM Wortmannin BdUTP 251.00 47 376.37 39 49.95% 
naive/activated 200uM Wortmannin BdUTP 242.62 28 538.04 45 121.76% 
naive/activated 200uM Wortmannin BdUTP 419.81 40 520.50 37 23.99% 
naive/activated 200uM Wortmannin BdUTP 575.38 46 904.59 38 57.22% 
naive/activated 200uM Wortmannin BdUTP 695.93 38 1080.32 29 55.23% 
  Total 553.86 ±101.82 289 809.87±122.12 296 46.22%  
naïve/activated 200uM Wortmannin H2AX 652.14 28 249.14 45 -53.70% 
naïve/activated 200uM Wortmannin H2AX 341.52 40 59.70 37 -82.52% 
naïve/activated 200uM Wortmannin H2AX 320.87 46 41.14 38 -87.18% 
naïve/activated 200uM Wortmannin H2AX 444.76 38 74.87 29 -83.17% 
  Total 411.30 ±50.19 152 106.21 ±48.14 149 -74.18%  
naive/activated 50uM LY294006 BdUTP 575.38 ±25.44 46 663.05 ±36.96 34 15.24%  
naive/activated 50uM LY294006 BdUTP 695.93 ±18.38 38 743.49 ±45.83 21 6.83% 
naive/activated 50uM LY294006 H2AX 320.87 ±11.90 46 443.94 ±28.06 34 38.36%  
naive/activated 50uM LY294006 H2AX 444.76 ±17.15 38 576.27 ±31.52 21 29.57%  
naive/activated 200uM LY294006 BdUTP 695.93 ±18.58 38 1064.32 ±49.29 33 52.93%  
naive/activated 200uM LY294006 BdUTP 245.62 ±8.44 44 370.56 ±9.12 34 50.87%  
naive/activated 200uM LY294006 H2AX 444.76 ±17.15 38 556.24 ±21.46 33 25.06%  
naive/activated 200uM LY294006 H2AX 209.99 ±12.72 44 313.79 ±16.70 34 49.43%  
 Table 3.2  PIKK inhibitors alleviate the block on DNA synthesis elongation
imposed on naïve S phase nuclei by damage-activated extract
Naïve S phase HeLa-S3 nuclei were incubated in damage-activated S phase HeLa-S3
extract supplemented with either 200µM wortmannin, 50µM LY294002 or 200µM
LY294002. Reactions were processed as described in the methods (Section 2.7), and
mean pixel intensities of BdUTP incorporation and H2AX phosphorylation for each
sample recorded using Openlab.  Table displays the mean pixel intensity of these
markers with standard error of the mean and the percentage change in fluorescence
between control reactions and reactions treated with inhibitor. Asterisks represent the
p-value found by paired t-test (total values) or t-test assuming unequal variances
(individual replicates):  = 0.05>p>0.01;  = 0.01>p>0.001;  p<0.001.
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Figure 3.5 PIKK inhibitors alleviate the block on DNA synthesis elongation
imposed on naïve S phase nuclei by damage-activated extract
Fluorescent images of sites of DNA replication and phosphorylated H2AX in naïve S
phase HeLa-S3 nuclei incubated in damage-activated S phase HeLa-S3 extract
supplemented with either 200µM wortmannin or 50µM LY294002. Reactions were
processed as described in the methods (Section 2.7). BdUTP incorporation was
visualised using streptavidin-fluorescein (green) and H2AX phosphorylation with
mouse monoclonal anti-phospho H2AX (Ser139) antibody, and anti-mouse Alexa
568 conjugated secondary antibody.  Nuclei were counterstained with Hoechst 33258
(blue).
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Figure 3.6 PIKK inhibitors stimulate DNA synthesis elongation in naïve S phase
nuclei incubated with naïve extract
Fluorescent images of sites of DNA replication and phosphorylated H2AX in naïve S
phase HeLa-S3 nuclei incubated in naïve S phase HeLa-S3 extract supplemented
with either 200µM wortmannin or 50µM LY294002. Reactions were processed as
described in the methods (Section 2.7). BdUTP incorporation was visualised using
streptavidin-fluorescein (green) and H2AX phosphorylation with mouse monoclonal
anti-phospho H2AX (Ser139) antibody, and anti-mouse Alexa 568 conjugated
secondary antibody.  Nuclei were counterstained with Hoechst 33258 (blue).
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nuclei in damage-activated extract. When incubated in naive extract, nuclei displayed 
constant levels of H2AX phosphorylation whether the inhibitor was added to the 
reaction or not (Table 3.3). 
3.4.4 Damaged nuclei condition cellular extract to inhibit DNA replication 
It has already been shown that activation of the DNA damage response is sustained in 
damaged nuclei when incubated in naive extract, and hypothesized that this is due to 
activation of soluble damage signalling in vitro by these nuclei. To test whether signals 
generated by damaged nuclei can activate the DDR in naive extract, naive extracts were 
exposed to nuclei containing etoposide-induced DSBs, during a “pre-conditioning 
reaction” before being cleared of nuclei by centrifugation. These “pre-conditioned” 
extracts were then incubated with naive nuclei to test their effect on DNA synthesis and 
H2AX phosphorylation. A significant suppression in capacity to support elongation of 
DNA synthesis was evident, compared to mock treated extract pre-exposed to naive 
nuclei (Figures 3.7a and 3.7b; Table 3.4). Thus events that activate the DDR as well as 
some of the consequences of DDR activation can be reconstituted in vitro. 
Condition Concentration Marker 
Mean untreated 
pixel intensity 
Sample 
size 
Mean treated 
pixel intensity 
Sample 
size 
Percentage 
change 
naïve/naïve 200uM Wortmannin BdUTP 1466.59 32 1538.92 32 4.93%  
naïve/naïve 200uM Wortmannin BdUTP 1411.12 35 1561.62 53 10.67% 
naïve/naïve 200uM Wortmannin BdUTP 555.53 41 764.13 59 37.55% 
naïve/naïve 200uM Wortmannin BdUTP 503.62 32 738.84 49 46.71% 
  Total 984.21±262.94 140 1150.88±230.69 193 16.93% 
naïve/naïve 200uM Wortmannin H2AX 349.45 ±19.00 35 96.28 ±7.23 28 -72.45%  
naïve/naïve 200uM Wortmannin H2AX 337.46 ±23.70 32 189.19 ±23.91 49 -43.94%  
naive/naive 50uM LY294006 BdUTP 503.62 ±18.58 32 721.78 ±28.32 33 43.32%  
naive/naive 50uM LY294006 H2AX 337.46 ±23.70 32 350.52 ±12.87 33 3.90% 
 
Table 3.3 PIKK inhibitors stimulate DNA synthesis elongation in naïve S phase
nuclei incubated with naïve extract
Naïve S phase HeLa-S3 nuclei were incubated in naïve S phase HeLa-S3 extract
supplemented with either 200µM wortmannin, 50µM LY294002 or 200µM
LY294002. Reactions were processed as described in the methods (Section 2.7), and
mean pixel intensities of BdUTP incorporation and H2AX phosphorylation for each
sample recorded using Openlab.  Table displays the mean pixel intensity of these
markers with standard error of the mean and the percentage change in fluorescence
between control reactions, and reactions treated with inhibitor. Asterisks represent
the p-value found by paired t-test (total values) or t-test assuming unequal variances
(individual replicates):  = 0.05>p>0.01;  = 0.01>p>0.001;  p<0.001.
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3.4.5 Cell free nuclei present an unique global pattern of H2AX phosphorylation 
One of the characteristic features of H2AX phosphorylation in damaged cells is its focal 
nature. These foci are specifically induced at the site of double strand breaks, and the 
number of them has previously been shown to correlate to the number of DNA lesions 
present in the nucleus (Sedelnikova, Rogakou et al. 2002). However the H2AX 
phosphorylation imposed by damage-activated cytosolic extract upon naive nuclei is not 
constrained to foci. Instead, a global pattern of phosphorylation is displayed, which is 
not evident in nuclei prior to incubation in cytosolic extract (Figures 3.8a and 3.8b). As 
this is induced independent of the presence of physical damage, a global pattern is not 
unexpected and implies that targeting of the kinases is impaired. However the presence 
of physical damage does not restore focal H2AX phosphorylation because a global 
pattern is also observed in damaged nuclei in vitro (Figure 3.3c). 
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Figure 3.7 DNA synthesis is inhibited in naïve S phase nuclei incubated with S 
phase extract preconditioned by exposure to damaged nuclei 
Naïve S phase HeLa-S3 extract was preincubated in either naïve or damaged S phase 
nuclei, before recovery by centrifugation to create mock activated or in vitro 
activated extracts. 
a) Fluorescent images of sites of DNA replication in naïve S phase HeLa-S3 nuclei 
incubated with mock and in vitro activated extract. Reactions were processed as 
described in the methods (Section 2.7). BdUTP incorporation was visualised using 
streptavidin-fluorescein (green).  Nuclei were counterstained with Hoechst 33258 
(blue). 
b) Quantification of BdUTP incorporated into nuclear DNA (blue) in cell-free 
reactions in which naïve nuclei are incubated in mock and in vitro activated extract. 
Histogram shows average fluorescent intensity with standard error of the mean, and 
is representative data from one of two independent experiments. N = number of 
nuclei quantified per sample. Asterisks represent the p-value found by single factor 
ANOVA:  = 0.01>p>0.001;  
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Figure 3.8 Global H2AX phosphorylation develops over the course of cell-free
reactions and is independent of DNA synthesis
a) Immunofluorescence images of H2AX phosphorylation in an etoposide-treated
HeLa-S3 cell and a naïve S phase HeLa-S3 nucleus after 30 minutes incubation in
damage-activated extract. H2AX phosphorylation was detected with mouse
monoclonal anti-phospho H2AX (Ser139) antibody, and anti-mouse Alexa 568
conjugated secondary antibody.
b) Immunofluorescence images of initial states of H2AX phosphorylation (red) in
naïve and damaged S phase HeLa-S3 nuclei. Nuclei were counterstained with
Hoechst 33258 (blue).
c) Fluorescence images of BdUTP incorporation (green) and H2AX phosphorylation
(red) in individual naïve S phase HeLa-S3 nuclei after 2 or 30 minutes incubation in
naïve or damage-activated S phase HeLa-S3 extract. BdUTP was detected using
fluorescein streptavidin. Nuclei were counterstained with Hoechst 33258 (blue).
d) Fluorescence images of BdUTP incorporation (green) and H2AX phosphorylation
(red) in individual naïve S phase HeLa-S3 nuclei over 30 minutes incubation in
damage-activated S phase HeLa-S3 extract supplemented with 200!M aphidicolin.
Nuclei were counterstained with Hoechst 33258 (blue).
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3.4.5.1 Extract-induced global H2AX phosphorylation develops rapidly in vitro 
To examine the development of global H2AX phosphorylation in naive nuclei, a time 
course was carried out over the course of a 30 minute cell-free incubation, combining 
naive nuclei with either naive or damage-activated extracts. The presence of any extract 
induced global H2AX phosphorylation in nuclei within 2 minutes of exposure, with 
greater levels of phosphorylation observed in those incubated in activated extract. The 
intensity of H2AX phosphorylation did not increase greatly between the 2 minute 
interval and the end of the 30 minute incubation (Figure 3.8c). 
3.4.5.2 Extract-induced H2AX phosphorylation is independent of DNA replication 
In an intact cell that has suffered DNA damage, ATM exclusively phosphorylates 
H2AX at the site of double strand breaks, which then act as a barrier to DNA replication 
elongation. However, ATM and H2AX phosphorylation have been found to also play a 
role in regulation of DNA replication (Shechter, Costanzo et al. 2004). This suggests 
two possible explanations for the global pattern of H2AX phosphorylation observed: 
either the removal of barriers to the propagation of H2AX phosphorylation, or the 
indiscriminate targeting of DNA damage signalling to all ongoing replication forks in 
the absence of DSBs. In order to test whether ongoing replication forks propagate 
H2AX phosphorylation in vitro, damage-activated extracts were supplemented with 
aphidicolin, an inhibitor of DNA replication, before incubation with naive nuclei. In the 
presence of 1mM aphidicolin, incorporation of biotinylated-dUTP into nuclear DNA 
was substantially reduced, but patterns of H2AX phosphorylation were unaltered, 
displaying global phosphorylation within 1 minute of exposure to activated extract 
(Figure 3.8d).  
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3.5 Discussion 
Work in this chapter shows that cell-free approaches can be adapted as the basis of 
DDR signalling activation assays, using phosphorylation of H2AX as a direct marker 
and inhibition of DNA synthesis elongation as a surrogate marker. From the 
experiments described here, it can be concluded that: 
• Inhibition of DNA synthesis and induction of H2AX phosphorylation are 
maintained in nuclei from damaged cells, even when activated cytosolic factors 
are replaced with naive cytosol. 
• Treating nuclei with damage-activated extract induces H2AX phosphorylation 
and inhibits DNA synthesis in both S and G1 phase nuclei, in the absence of 
DNA lesions. 
• DSB-containing nuclei are able to activate soluble components of DNA damage 
signalling in vitro, reconstituting upstream events of the DDR as well as 
downstream phosphorylation of H2AX. 
• Both induction of H2AX phosphorylation and inhibition of DNA synthesis in 
vitro are dependent on PIKK activity. H2AX phosphorylation occurs 
independently of DNA synthesis.  
These conclusions give rise to some interesting questions about the nature of DNA 
damage response signalling in this system and in general, which are discussed below. 
3.5.1 Nuclei in cytosolic extract display a base level of H2AX phosphorylation 
When naive nuclei were incubated in naive extract, a base level of global H2AX 
phosphorylation was observed. This phosphorylation was lower than that observed 
when damaged or damage-activated components were used, but was clearly induced by 
the exposure of nuclei to cytosolic extract. Not all naive nuclei were free of focal H2AX 
phosphorylation upon harvesting, but those foci induced by thymidine exposure and the 
physical stress of cell lysis were minimal, and present at a far lower frequency than in 
nuclei from cells treated with etoposide. When a double strand break occurs in vivo, a 
positive feedback loop is formed between γH2AX, MDC1 and ATM, propagating 
spread of H2AX phosphorylation throughout megabase-size regions of chromatin (Lou, 
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Minter-Dykhouse et al. 2006). It seems likely that with the absence of cell membranes, 
soluble DDR signalling proteins in the cytosolic extract surrounding the nuclei allow 
this feedback mechanism to generate a disproportionate imposition of H2AX 
phosphorylation throughout the entire population.  
The nature of the cell line used to generate nuclei and extracts may also contribute to 
this base level of H2AX phosphorylation. The S3 HeLa cell line is a subclone of the 
HeLa cell line, which was derived from a human epithelial cervical cancer. Constitutive 
phosphorylation of H2AX, ATM, Chk2 and p53 is a common feature of the early stages 
of cancer (Bartkova, Hořejši et al. 2005; Gorgoulis, Vassiliou et al. 2005; Srivastava, 
Gochhait et al. 2008), and might be partly responsible for the small proportion of nuclei 
displaying γH2AX foci following harvesting. An initial experiment was carried out to 
investigate whether this base level of H2AX phosphorylation was observed in nuclei 
from non-cancerous cells using undamaged S phase WI38 nuclei. These nuclei did 
support DNA elongation, and appeared to show a drop in BdUTP incorporation when 
incubated in damage-activated extract compared to naive extract, but levels of H2AX 
phosphorylation were high in both samples. Nuclei that had not been exposed to extract 
were also visualised, however very low numbers of these nuclei were retained upon the 
polylysine-coated coverslips used. Unlike S3 HeLa nuclei, the few attached WI38 
nuclei displayed no initial H2AX phosphorylation, suggesting that this phosphorylation 
was not due to nuclei from healthy cell lines being less able to withstand the preparation 
conditions. Instead it is more likely to result from the use of cytosolic extract from 
cancerous cells, which contain physiological alterations and mutations conferring 
resilience to damage signalling pathways that are not found within the WI38 cell line.  
The less robust nature of WI38 cells and their slow doubling time, meant that while a 
small number of nuclei could be harvested relatively easily on a one off basis, applying 
damage treatments and growing cells up in bulk to harvest cytosolic extract was not 
feasible. Given these factors, previous optimisation of the harvesting and assay protocol 
for S3 HeLa cells, and that S3 HeLa nuclei and extracts display a clear differential in 
H2AX phosphorylation and BdUTP incorporation when components from etoposide-
treated cells are used, experimentation was continued using this cell line regardless of 
the base level of H2AX phosphorylation shown. 
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3.5.2 Induction of H2AX phosphorylation in the absence of DNA lesions 
These data show that damage-activated extracts contain soluble signalling molecules 
that are able to target chromatin regardless of the presence of physical DNA damage, 
inhibiting DNA synthesis in both S and G1 phase naive nuclei. Furthermore in S phase 
nuclei effective phosphorylation of H2AX is induced in the absence of DNA lesions 
(G1 nuclei were not examined). A recent paper has been published demonstrating the 
induction of local H2AX phosphorylation in the absence of damage when proteins in 
the DDR signalling pathway were fused to chromatin for a prolonged period (Soutoglou 
and Misteli 2008). Soutoglou and Misteli concluded that the stable association of repair 
factors with chromatin is required for triggering, amplifying and maintaining DDR 
signalling, which is consistent with these results. The H2AX phosphorylation observed 
in my experiments takes place far more rapidly than that previously observed, and 
occurs throughout the nucleus, reflecting the mass of activated signalling factors present 
in damage-activated extracts compared to the specific targeting of a small region of 
chromatin.  
3.5.3 Recreation of multiple stages of DNA damage response signalling  
Damaged nuclei were also used to activate signalling in naive extract, to produce “in 
vitro activated extract”, which was then shown to inhibit BdUTP incorporation and 
induce H2AX phosphorylation in naive nuclei. While these experiments confirm the 
ability of DSB-containing nuclei to activate soluble components of the DDR pathway in 
vitro, the drop in biotinylated-dUTP incorporation was less than half of that produced 
by extracts harvested directly from etoposide treated cells. Thus in vitro induction of the 
DDR does not occur with the same efficiency when reconstituted in vitro. For this 
reason, directly damage-activated extracts were used for the majority of experiments, 
rather than further investigating the capacity of pre-conditioned extract.  
3.5.4 H2AX phosphorylation and inhibition of DNA synthesis are both regulated 
by PIKKs but are independent of each other  
H2AX phosphorylation induced by activated extract appears to localise with sites of 
replication elongation during the early stages of cell-free reactions. Recent research has 
suggested roles for ATM, ATR and H2AX in regulation of DNA replication initiation 
and elongation, and at first glance could present an explanation for this observation 
(Marheineke and Hyrien 2004; Shechter, Costanzo et al. 2004). However, when 
 70 
damage-activated extracts are supplemented with aphidicolin no decrease in H2AX 
phosphorylation is observed, showing that phosphorylation is not propagated by 
ongoing replication forks.  
3.5.4.1 Disruption of DDR signalling targeting 
The fact that the H2AX phosphorylation observed by Soutoglou (Soutoglou and Misteli 
2008) was restrained to the areas in which proteins such as NBS1, MRE11 and MDC1 
were fused to chromatin, suggests that the global H2AX phosphorylation observed in 
the cell-free system may be due to disruption of DDR signalling targeting leading to 
binding of these proteins across the entirety of the chromatin. This would not require 
any reliance upon DNA synthesis, although the areas where DNA is unwound for 
replication may prove more accessible and be targeted first in the absence of physical 
DNA lesions, explaining the initial co-localisation with sites of replication observed. As 
the cell-free reaction progresses, H2AX phosphorylation is likely to spread out from 
these areas due to the feedback mechanisms previously described, leading to saturation 
of the chromatin, and overwriting the initial fine focal pattern. While H2AX 
phosphorylation in the cell-free system is not linked to DNA synthesis, the stimulation 
of BdUTP incorporation by PIKK inhibitors in naive nuclei and extract, as well as in 
nuclei treated with damage-activated extract, is consistent with a role for ATM and 
γH2AX in the control of DNA replication elongation.  
3.5.4.2 Deregulation of DNA damage detection and repair from delayed DNA synthesis 
in the presence of LY294002 
While wortmannin abolished H2AX phosphorylation and stimulated BdUTP 
incorporation, treatment with LY294002 stimulated BdUTP incorporation without any 
negative effect on H2AX phosphorylation. Furthermore, in reactions containing 
damage-activated extracts, levels of H2AX phosphorylation showed a significant 
increase. It is known that unlike the G1-S and G2-M checkpoints, in which progress 
through the cell cycle is actively delayed until set events have been completed, the intra-
S phase checkpoint does not operate by bringing an abrupt halt to DNA replication, but 
rather by slowing the rate at which it occurs, allowing damage to be repaired (Rhind and 
Russell 2000; Willis and Rhind 2009). As such, the fact that DNA synthesis is 
continuing in the presence of H2AX phosphorylation is not unusual - this is routinely 
observed in the experiments in this chapter - but the significant increase in rate suggests 
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LY24002 induces deregulation of the mechanisms linking DNA damage detection and 
repair with slowed replication rates.  
H2AX phosphorylation can be mediated by one or more of ATM, ATR and DNA-PK, 
dependent on the cause of damage. Phosphorylation of ATM in response to etoposide 
treatment is well documented, however the ATR-dependent Chk1 pathway is also 
activated in HeLa cells in response to 15µM etoposide treatment (Fu, Wan et al. 2008; 
Jamil, Mojtabavi et al. 2008; Rudolf, Cervinka et al. 2009; Nam, Doi et al. 2010). 
Furthermore, siRNA inhibition of DNA-PK in HeLa cells has been shown to increase 
sensitivity to etoposide treatment (Tian, Chen et al. 2007), suggesting that all three 
kinases play a role in the response to etoposide-induced double strand breaks. 
While wortmannin and LY294002 are both known inhibitors of the PIKK family, they 
have different modes of action, and vary considerably in effectiveness. Wortmannin 
inhibits DNA-PK, ATM and ATR at a concentration of 200µM (Sarkaria, Tibbetts et al. 
1998; Rodriguez-Bravo, Guaita-Esteruelas et al. 2006). LY294002 is an effective 
inhibitor of DNA-PK, with an IC50 of 1-5µM, however studies examining its effects on 
ATM have given contradictory results. In a 2004 study characterising purified ATM, 
Goodarzi reports that LY294002 inhibits ATM with an IC50 of 6µM (Cheatham, 
Vlahos et al. 1994), however in an in vitro study Stiff shows that treatment with 
LY294002 inhibits DNA-PK dependent H2AX phosphorylation in ATM-deficient 
chicken cells, but does not prevent phosphorylation in ATM-competent cells lacking 
DNA-PK (Stiff, O'Driscoll et al. 2004). A concentration of 1mM LY294002 is required 
to effectively inhibit ATR (Hall-Jackson, Cross et al. 1999). It seems consistent with 
Stiff’s findings that the concentrations used for this chapter (50 and 200µM) inhibit 
DNA-PK, but not ATM or ATR, alleviating restrictions on DNA synthesis without 
affecting early DDR signalling. Future work would benefit from analysis with an 
antibody for phosphorylated ATM in order to clarify this point. Stimulation of BdUTP 
incorporation by LY294002 suggests that inhibition of the ATR signalling pathway is 
not required to relieve restraints upon DNA synthesis during S phase, and that this may 
also apply to ATM.  
Previous results suggest that activated soluble signalling elements present in damage-
activated extracts are most easily able to bind to regions of the chromatin where the 
DNA is being unwound to allow replication. If LY294002 is alleviating signalling 
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pathways that restrain DNA synthesis without inhibiting the phosphorylation of H2AX 
and consequent downstream DDR signalling, then ongoing DNA replication elongation 
may provide more sites to which activated DDR proteins can bind, and from which 
H2AX phosphorylation can spread leading to greater levels of nuclear γH2AX. 
3.5.5 Potential applications of the cell-free system  
In addition to the biological implications already discussed, this cell-free system has 
potential for a number of research applications.  
3.5.5.1 Assay for inhibitors 
Use of wortmannin and LY294002 has shown that we can see an effect of PIKK 
inhibitors upon the DDR using this system. These results demonstrate how this cell-free 
system can be used as a simple screening tool for small molecule inhibitors of the DNA 
damage response in a system that is uncomplicated by the presence of damage, and 
which is isolated from the process of DNA repair. Soluble factors present in activated 
extracts recreate both G1/S and intra-S phase checkpoints, and upstream events that 
signal the activation of soluble components of the DDR have also been reconstituted in 
vitro, providing multiple targets against which inhibitory small molecules could be 
selected. The University of York has patent protected this system (reference number 
3079P/GB), and its value as a screening tool in comparison to existing assays is 
discussed in greater detail in the final discussion (Chapter 6). While phosphorylation of 
H2AX acts as a clear and reproducible marker of early DDR signaling, the system can 
also potentially be used in combination with other antibodies, such as those for 
phosphorylated ATM, ATR, Chk1 and Chk2, to more closely dissect whereabouts in 
these pathways inhibitors are acting.  
3.5.5.2 Studying the role of Ciz1 in the DNA damage response 
This cell-free system can be used to investigate the roles of novel proteins implicated in 
the DNA damage response. Such applications include examining the effect of titrating 
proteins into cell-free reactions and asking if an effect on H2AX phosphorylation or 
DNA synthesis is shown, and use of damage-activated extracts to modify substrates of 
ATM and ATR in vitro. This system has been used to investigate the role of Ciz1 in the 
DNA damage response, and use of it for this purpose is discussed in Chapters 4 and 5. 
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Chapter 4 
CHARACTERISATION OF CIZ1’S SQ/TQ MOTIFS 
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4.1 Introduction 
A role for Ciz1 in regulation of DNA replication has been established by the Coverley 
laboratory (Coverley, Marr et al. 2005; Ainscough, Rahman et al. 2007), but evidence 
has also been found implicating it in the DNA damage response. Experiments have 
previously suggested a correlation between Ciz1 overexpression and induction of 
H2AX phosphorylation, and Ciz1 is commonly misspliced in cancerous cells (Rahman, 
Ainscough et al. 2007). Most notably, Ciz1 contains a number of SQ/TQ motifs, which 
are commonly phosphorylated by ATM and ATR (Kim, Lim et al. 1999; O'Neill, 
Dwyer et al. 2000). These motifs are often found in clusters and their presence is 
thought to be indicative of DNA damage response proteins (Traven and Heierhorst 
2005).  Human Ciz1 contains 21 S/TQ motifs, and mouse Ciz1 contains 18 grouped in 3 
clusters. One of the SQ motifs in human Ciz1 has already been shown to be 
phosphorylated in response to ionising radiation (Matsuoka, Ballif et al. 2007), however 
this particular site is not present in mammalian homologues.  This chapter uses the cell 
free system described in Chapter 3 along with other tools to investigate whether SQ/TQ 
motifs in the murine splice variant, ECiz1, are phosphorylated as part of the DNA 
damage response. 
4.2 Aims 
This chapter aimed to use the cell free system and other methods to investigate 
phosphorylation of Ciz1 in response to DNA damage. 
Goals were: 
• To carry out bioinformatic characterisation of Ciz1 SQ/TQ motifs 
• Detection and dissection of SQ/TQ phosphorylation in Ciz1 
4.3 Experimental design 
To adapt the cell free system to carry out phosphorylation assays, GST-tagged Ciz1 
protein and protein fragments were attached to GST beads and incubated in naive or 
damage-activated extracts (Figure 4.1), before being separated out by centrifugation and 
run on western blot. Phospho-(Ser/Thr) ATM/ATR substrate antibody was then used to 
identify phosphorylated protein.  Full length murine GST-ECiz1, an N-terminal 
fragment GST-ECiz1 N442 and a C-terminal fragment GST-ECiz1 C274 were used for 
these experiments. 
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4.4 Results 
4.4.1 Bioinformatic analysis of Ciz1 SQ/TQ sites 
4.4.1.1 SQ/TQ motifs form clusters within Ciz1 
Clustering of SQ/TQ motifs is a common feature of DDR proteins, and their presence is 
thought to be indicative of potential involvement in the response. Using a stringent 
definition of an SQ/TQ cluster domain (SCD), in which there are 5 or more SQ/TQ 
motifs, separated by no more than 35 amino acids each, 1% of all mammalian and yeast 
proteins contain one or more SCDs. In 2002, 10% of these SCD-containing proteins had 
been identified as having a role in the DDR (Schwartz, Duong et al. 2002). Not only 
does human Ciz1 contain an SCD in exon 8 by this definition, but also two other 
smaller clusters of SQ/TQ motifs spread across the protein. Different exons of both 
human and mouse Ciz1 were grouped into sections of the protein with approximately 
equal sequence lengths, as displayed in Figure 4.1, and the statistical likelihood of the 
number of motifs falling in each section analysed using the chi-squared test. p-values 
were significant in both human and mouse for exon 8, and in mouse for exons 14-17, 
showing it to be statistically unlikely that motifs are evenly spread across the protein by 
chance, and reinforcing the idea that clustering of SQ/TQ motifs is occurring in Ciz1. 
4.4.1.2 SQ/TQ motif frequency in Ciz1 is comparable with that of known DDR proteins 
The statistical likelihood of an SQ/TQ motif occurring is one in every two hundred 
amino acid residues. Human Ciz1 contains 21 SQ/TQ motifs, equivalent to one site 
every 43 residues. This frequency is higher than that seen in the known DDR proteins 
BRCA1, 53BP1, CREB-binding protein and MDC1, which vary between one every 61 
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involvement in the PIKK pathways, such as actin 1, ribonuclease III and caspase-
activated nuclease, a considerable drop in frequency is seen, with over 300 amino acid 
residues per motif. 
4.4.1.2 SQ/TQ motif frequency in Ciz1 is comparable with that of known DDR proteins 
The statistical likelihood of an SQ/TQ motif occurring is one in every two hundred 
amino acid residues. Human Ciz1 contains 21 SQ/TQ motifs, equivalent to one site 
every 43 residues. This frequency is higher than that seen in the known DDR proteins 
BRCA1, 53BP1, CREB-binding protein and MDC1, which vary between one every 61 
residues, and one every 93 (Table 4.2). If this is compared to proteins with no suspected 
involvement in the PIKK pathways, such as actin 1, ribonuclease III and caspase-
activated nuclease, a considerable drop in frequency is seen, with over 300 amino acid 
residues per motif.  
4.4.1.3 Scansite predicts phosphorylation of Ciz1 SQ/TQ motifs 
Scansite is a program that predicts sites within an amino acid sequence which are likely 
to be targeted by protein kinases, using a matrix of selectivity values to assess 
likelihood of phosphorylation of short sequences (Obenauer, Cantley et al. 2003).  It 
also predicts corresponding surface accessibility of amino acids, based solely on 
sequence. The Scansite motif search operates at three different stringencies set by the 
percentile of variation from a library of known motifs that the protein falls into 
compared to all other vertebrate proteins contained in SwissProt. These percentiles are 
the top 0.2% (high), 1% (medium) and 5% (low) of sequence matches.  At varying 
stringencies, human Ciz1 is predicted to contain between 1 and 18 potential DNA 
damage kinase phosphorylation motifs, the majority of which are SQ/TQ sites. Figure 
4.1 displays the location of all SQ/TQ motifs in human Ciz1, highlighting the fourteen 
ScanSite predicts to be phosphorylated by the DNA damage kinases, ATM or DNA-PK, 
in a low stringency search. Also shown are four serine and threonine residues predicted 
to be targeted by ATM and DNA-PK by this search, which are not immediately 
followed by glutamine. Lending credence to the efficacy of ScanSite’s search is the fact 
that the site identified as most likely to be phosphorylated is the threonine residue 
identified by Matsuoka (Matsuoka, Ballif et al. 2007), which it predicts to be a substrate 
of DNA-PK. 
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4.4.2 Confirmation of ECiz1 phosphorylation in vitro 
In Chapter 3 it was demonstrated that soluble PIKK-mediated DDR signalling proteins 
are present in cytosolic extract from etoposide-treated cells, and capable of 
phosphorylating H2AX in undamaged nuclei. Here, these extracts are used to 
demonstrate PIKK-dependent phosphorylation of SQ/TQ motifs in Ciz1. 
4.4.2.1 ECiz1 SQ/TQ motifs are phosphorylated by exposure to damage-activated 
extract    
In order to investigate phosphorylation of Ciz1 in vitro, a GST-tagged murine 
embryonic splice variant of Ciz1 was used. ECiz1 is found in 11 day mouse embryos, 
and has been shown to stimulate DNA synthesis initiation and elongation and to form  
foci within the nuclei (Coverley, Marr et al. 2005; Rahman, Ainscough et al. 2007). 
Unlike full length Ciz1, ECiz1 can be expressed and purified in bacteria easily. As 
ECiz1 is a murine splice variant, it does not contain a homologue of the motif identified 
by Matsuoka, but does contain 13 other SQ/TQ motifs (Figure 4.3a). GST-tagged ECiz1 
was bound to GST beads and incubated for thirty minutes in these damage-activated 
extracts, which were prepared and supplemented as for the assays described previously.  
When retrieved and probed by Western blot for phosphorylated SQ/TQ motifs, ECiz1 
incubated in damage-activated extract displayed a clear band compared to that 
incubated in naive extract, or untreated ECiz1, and of identical size to that detected 
when probed with the anti-Ciz1 antibody 1793 (Figure 4.3b).  
4.4.2.2 Phosphorylation of SQ/TQ motifs in ECiz1 is dependent on PIKKS 
To verify the PIKK-dependent nature of the SQ/TQ phosphorylation observed in Figure 
4.3b, damage-activated extracts were supplemented with either 200µM wortmannin or 
200µM LY294002 prior to incubation with GST-ECiz1. When treated with either PIKK 
inhibitor, phosphorylation could not be detected (Figure 4.3c). In Chapter 3.5.4.2 the 
properties of LY294002 in the cell free system are discussed and it is established that 
they are consistent with inhibition of DNA-PK but not ATM or ATR, while wortmannin 
inhibits all three. As both inhibitors prevent phosphorylation of ECiz1 by damage-
activated extracts, it suggests that this phosphorylation is dependent upon DNA-PK, 
rather than upon ATM or ATR. This could potentially be tested using a DNA-PK 
specific inhibitor.  
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4.4.3 Locating phosphorylated motifs in ECiz1 
Of the 13 SQ/TQ sites spread across ECiz1, 10 are predicted to be ATM or DNA-PK 
phosphorylation sites by a low stringency ScanSite search (Figure 4.4a). To establish 
which section of the protein was being phosphorylated two fragments of ECiz1, GST 
ECiz1-N442 (N442) and GST ECiz1-C274 (C274), were used (Figure 4.4b).   
4.4.3.1 SQ/TQ phosphorylation is only detected in vitro in the C-terminus of ECiz1 
GST-tagged N442 and C274 were incubated in damage-activated extract before 
retrieval by centrifugation, and probed by Western blot for SQ/TQ phosphorylation. 
While the 1793 antibody could be used to detect N442, as this is an antibody against the 
N-terminal region of the protein, it could not be used to detect C-terminal regions.  
Instead an anti-GST antibody was used to detect the GST-tag in fragment C274. No 
phosphorylation could be observed in N442, however C274 displayed a phosphorylated 
band of identical size to that found by the anti-GST antibody (Figures 4.4c and d). 
When damage-activated extract was supplemented with 200µM wortmannin prior to 
incubation, the intensity of this phosphorylated band was considerably diminished 
(Figure 4.4d).  
4.4.3.2 Mutation of serine and threonine residues in the C-terminus of ECiz1 shows 
little effect upon overall phosphorylation levels in vitro 
Following detection of SQ/TQ phosphorylation in C274, a GST-tagged construct with 
three of the four SQ/TQ motifs in the C-terminal region of ECiz1 replaced by AQ, 
rendering them unable to be phosphorylated, was generated by PCR point mutation 
(Figure 4.4b).  This construct, GST ECiz1 AQ1-3 (AQ1-3), was used to purify protein 
that could be used for cell-free assays. When AQ1-3 was incubated with damage-
activated extract SQ/TQ phosphorylation could still be detected compared to untreated 
protein (Figure 4.4e). While this phosphorylation is at a slightly lower intensity than 
that observed in an unaltered GST-ECiz1 control, the quality of the blot and intensity of 
the 1793 bands produced by sheer quantity of protein purified make it difficult to tell 
whether this is due to lower levels of AQ1-3 retrieved, or a genuine decrease in 
phosphorylation. 
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Figure 4.4 ECiz1 fragment C274 is phosphorylated in a PIKK-dependent 
manner when exposed to damage-activated extract 
a) Schematic of ECiz1 showing predicted DDR motifs and functional domains 
against predicted surface accessibility of individual amino acid residues. SQ/TQ 
motifs predicted to be phosphorylated by ATM or DNA-PK by Scansite are marked 
in red. 
b) Schematics of constructs used for fragment phosphorylation assays. GST ECiz1 
N442 and C274 fall within the replication and anchor domains of ECiz1 respectively. 
The SQ/TQ motifs mutated to prevent phosphorylation in GST ECiz1 AQ1-3 are 
marked in grey. 
c) Purified GST ECiz1 N442 was incubated in naïve and damage-activated S phase 
HeLa extract. Reactions were processed as described in the methods (Section 2.7) 
and retrieved protein was added directly to 2x loading buffer.  Protein bands were 
separated by 6.5% SDS-PAGE, and analysed using antibodies raised against Ciz1 
and phosphorylated SQ/TQ sites.   
d) Purified GST ECiz1 C274 was incubated in naïve and damage-activated S phase 
HeLa extract. Reactions were processed as described in the methods (Section 2.7) 
and retrieved protein was added directly to 2x loading buffer.  Protein bands were 
separated by 6.5% SDS-PAGE, and analysed using antibodies raised against GST 
and phosphorylated SQ/TQ sites.  
e) Purified GST ECiz1 AQ1-3 was incubated in naïve and damage-activated S phase 
HeLa extract. Reactions were processed as described in the methods (Section 2.7) 
and retrieved protein was added directly to 2x loading buffer.  Protein bands were 
separated by 6.5% SDS-PAGE, and analysed using antibodies raised against GST 
and phosphorylated SQ/TQ sites.  
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4.4.4 SQ/TQ motifs in Ciz1 fragments are not detectably phosphorylated when 
cells are exposed to etoposide 
As an alternative approach to detecting SQ/TQ phosphorylation across different regions 
of Ciz1, NIH3T3 cells transfected with GFP-tagged N-terminus N442 or C-terminus 
C274 Ciz1 were allowed to express for 20.5 hours prior to a 3 hour treatment with 
20µM etoposide. NIH3T3 cells were used as they are easily transfected using an Amaxa 
Nucleofector kit, unlike HeLa-S3 cells which displayed a very low transfection 
efficiency. Fragments of Ciz1 were used rather than full length Ciz1, in an attempt to 
reflect the difference in SQ/TQ phosphorylation seen between N- and C-terminal 
regions in section 4.4.3.1. Cells were then stained for SQ/TQ phosphorylation by 
immunofluorescence using the phospho-SQ/TQ antibody described previously. While 
detectable nucleus-wide SQ/TQ phosphorylation was successfully induced by damage, 
no difference in phosphorylation could be seen between GFP-expressing and 
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untransfected cells with either protein fragment, in either control or etoposide-treated 
cells (Figure 4.5). Without a specific antibody against modified Ciz1 SQ/TQ motifs, it 
is difficult to search for phosphorylation in vivo. This experiment relies upon addition of 
large quantities of truncated protein to cells, and the failure to detect phosphorylation of 
either ECiz1 fragment may reflect preferential interaction of PIKKs with correctly 
targeted and processed endogenous Ciz1 over partial proteins with potentially disrupted 
structure.  
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4.5 Discussion 
Work in this chapter shows that damage-activated cell-free extracts in combination with 
phosphorylation sensitive antibodies can be used to carry out DDR signalling activation 
assays upon purified proteins. The PIKK-dependent nature of the phosphorylation 
induced is verified by the use of the inhibitors wortmannin and LY294002, the 
inhibitory properties of which were validated in chapter 3. Using this system to 
investigate Ciz1, it can be concluded that ECiz1 is phosphorylated by soluble DDR 
signaling elements present in damage-activated cytosolic HeLa extract, and that this 
phosphorylation can be traced to the C-terminal region of the protein. These conclusions 
give rise to the question of what role phosphorylation of SQ/TQ motifs in Ciz1 might 
play, and whether any clues as to this can be gained from examination of Ciz1’s 
structural features and known functions, or from any similarities to proteins with known 
DNA damage response roles. The restrictions of the system used, and their implications 
for detection of modified proteins should also be considered. 
4.5.1 Obstacles to detection of phosphorylated SQ/TQ motifs 
Large scale screens have been carried out to identify substrates of the PIKK family 
which display phosphorylated SQ/TQ motifs in response to both ionising radiation and 
UV exposure (Matsuoka, Ballif et al. 2007; Stokes, Rush et al. 2007). While three main 
types of SCD-containing proteins have been identified - mediators linking ATM/ATR 
to other proteins, CHK1&2-like kinases and checkpoint effectors with roles in DNA 
repair or cell cycle arrest (Zhou and Elledge 2000; Nyberg, Michelson et al. 2002) - 
these studies implicate proteins in many processes in the DNA damage response, 
ranging from the predictable such as oncogenesis, transcriptional regulation and cell 
cycle regulation, through to more diverse pathways such as immunity, developmental 
processes and intracellular protein transport. In one of these studies phosphorylation of 
a Ciz1 TQ motif was detected in response to ionizing radiation, however this motif is 
only found in human Ciz1 (Matsuoka, Ballif et al. 2007). This chapter confirms 
phosphorylation of one or more SQ/TQ motifs in murine ECiz1 in response to 
etoposide-induced double strand break, and traces this phosphorylation to the C-
terminus of the protein. However mutation of three out of the four C-terminal SQ/TQ 
motifs does not eliminate phosphorylation of ECiz1 in damage-activated extract. 
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4.5.1.1 Varying efficacy of phospho-specific antibodies 
While phosphorylation of SQ/TQ motifs in the N-terminal fragment N442 could not be 
detected following incubation in damage-activated extract, modification of this region 
cannot be ruled out.  The anti-phospho SQ/TQ antibody was raised against synthetic 
phospho-(Ser/Thr) ATM/ATR substrate peptides, and preferentially targets phospho-
serine/threonine residues preceded by leucine or other hydrophobic amino acids at the -
1 position and followed by glutamine at the +1 position, making it unlikely to bind 
phosphorylated motifs preceded by a non-hydrophobic residue. Using a non-protein 
specific antibody increases the chance of binding, but also has a risk of missing 
phosphorylated motifs due to regional variation in structure, charge and hydrophobicity. 
By way of example, the Matsuoka study used a total of sixty eight phospho-(Ser/Thr) 
targeting antibodies including the Cell Signaling antibody used here.  Of these only one 
bound to a Ciz1 peptide, an anti-Phospho RPA32 (S33) Antibody (Bethyl Laboratories) 
(Matsuoka, Ballif et al. 2007). The failure of the Cell Signaling antibody to detect this 
modification may be due to peptide size and structure, but reflects the fact that while 
this antibody is well-characterised and commonly used for DDR research, one antibody 
cannot be relied upon to detect all modified motifs within a protein. Given that 
truncation of ECiz1 to create the N442 fragment may cause changes in folding, 
affecting surface accessibility of motifs and the ability of the antibody to bind, it is not 
certain that continued phosphorylation of ECiz1 AQ1-3 solely reflects the one 
unmutated motif remaining in the C-terminus of the protein. 
4.5.1.2 Limitations of using a single DNA damaging agent 
As demonstrated by the wide variety of proteins in which phosphorylation occurs, 
SQ/TQ modification is a widespread feature of DNA damage signalling, and has been 
shown to operate via several mechanisms. Phosphorylated SCDs in both mediators and 
Chk2-like kinases commonly bind to forkhead-associated (FHA) domains in other 
molecules and proteins, facilitating recruitment, oligomerization and auto-
phosphorylation of checkpoint kinases (Xu, Tsvetkov et al. 2002; Lou, Minter-
Dykhouse et al. 2003).  However as FHA domains only require one phosphorylated 
threonine residue to bind to, SQ motifs are redundant for this purpose. Evidence has 
been found that SQ/TQ motifs also bind to BRCA1 C-terminal (BRCT) domains 
(Manke, Lowery et al. 2003; Furuya, Poitelea et al. 2004), and along with the fact that 
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serine phosphorylation in SQ motifs has been observed in vivo (Gatei, Zhou et al. 
2001), suggests that FHA domain interaction is not the sole mode of action of SQ/TQ 
motif function.  
Further evidence for the sophisticated nature of SQ/TQ-dependent signalling is given by 
the range of requirements for activation of downstream signalling. In the yeast protein’s 
Chk2 homologue, Rad53, and its precursor, Rad9, individual SQ/TQ motifs are 
redundant, and a threshold of SQ/TQ phosphorylation across the protein must be 
reached in order for signalling to be propagated further (Schwartz, Duong et al. 2002; 
Lee, Schwartz et al. 2003). By contrast, in mammalian Chk2 SQ/TQ motifs have been 
found to have individual importance (Melchionna, Chen et al. 2000). One of the best 
characterised SCD-containing proteins, BRCA1, takes this to extremes, with the SQ/TQ 
motif required for downstream signalling to occur not only reliant upon the type of 
DNA damage experienced but the current stage of the cell cycle (Gatei, Zhou et al. 
2001; Xu, O'Donnell et al. 2002). The experiments here have only examined etoposide-
induced DSB signalling in cytosolic extracts from S phase cells, and it is not unlikely 
that were different sources of damage to be utilised, variations in SQ/TQ 
phosphorylation across ECiz1 might be observed.  
4.5.2 Functional domains of ECiz1 
As limited knowledge is available about general mechanisms of phosphorylation-
dependent SQ/TQ signalling, it is impossible to state a clear cut function of the 
phosphorylated motifs in Ciz1 and ECiz1. However it is possible to examine known 
features of the protein and speculate upon their impact upon the DNA damage response. 
A number of key features of Ciz1 have previously been identified, and the protein 
divided into two main regions: the N-terminal domain, required for stimulation of DNA 
replication initiation and ongoing synthesis (Coverley, Marr et al. 2005; Copeland, 
Sercombe et al. 2010), and the C-terminal domain, which is vital for recruitment of Ciz1 
to nuclear foci (Ainscough, Rahman et al. 2007). As detectable SQ/TQ phosphorylation 
has been limited to the C-terminus to date, discussion will focus on the features of this 
region. 
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4.5.2.1 Matrix binding region 
While it was originally expected that any SQ/TQ phosphorylation found in ECiz1 
would be traced to the N-terminal region of the protein, due to its involvement in 
replication, the presence of a nuclear matrix binding domain in the C-terminus gives 
rise to the possibility that SQ/TQ phosphorylation might affect Ciz1’s DNA replication 
stimulating properties by modulating its recruitment to the nuclear matrix. The nuclear 
matrix binding domain spans amino acids 708 to 830, and in its absence, recruitment of 
Ciz1 to DNAse and high salt-resistant nuclear structures is abolished (Ainscough, 
Rahman et al. 2007). During S phase these matrix-associated foci have been shown to 
co-localise with newly synthesised DNA, and evidence suggests that they coordinate 
delivery of cyclin A to the pre-replication complex (Copeland, Sercombe et al. 2010). 
Ciz1 has also been shown to stimulate DNA replication elongation during S phase, and 
given the slowing of DNA synthesis is an integral part of the response to DNA damage, 
inhibiting Ciz1’s ability to bind to the nuclear matrix could contribute to this.  
Alternatively, should Ciz1 possess an active role in DNA damage signalling, 
phosphorylation of this domain might induce recruitment of Ciz1 to nuclear matrix foci 
of DDR proteins as has already been observed in the cases of Rad51, Rad54, BRCA1 
and BRCA2 (Mladenov, Anachkova et al. 2006).  
4.5.2.2 C2H2 zinc finger 
The C-terminal region of Ciz1 also contains a zinc finger domain, the function of which 
has not yet been identified.  Initially zinc fingers were thought to be primarily involved 
in DNA binding, however evidence has been accumulating for RNA and protein 
binding too (Pieler and Bellefroid 1994; Brown 2005; Gamsjaeger, Liew et al. 2007).  A 
variety of different zinc finger domains exist, however that found in Ciz1 is a 
“classical” C2H2 domain. C2H2 zinc finger domains are commonly found in oncogenes 
and tumour suppressors, and their damage and distortion in DDR proteins due to 
presence of toxic metal ions, or dietary zinc deficiency is thought to be a factor in 
carcinogenesis (Witkiewicz-Kucharczyk and Bal 2006).  
There are three distinct classes of C2H2 zinc fingers – triple-C2H2, multiple-adjacent-
C2H2 and separated-pair-C2H2 (Iuchi 2001). Triple and separated pair zinc fingers are 
only capable of binding one ligand at a time, whereas multiple adjacent zinc fingers can 
bind multiple substrates. Ciz1 contains a triple-C2H2 zinc finger, similar to those found 
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in the C-terminal region of Krüppel-like factors (KLFs). Krüppel-like factors regulate 
transcription of cell cycle control factors and act as tumour suppressors, especially in 
endocrine-linked malignancies (Simmen, Pabona et al. 2010).  A number of the KLF 
family proteins regulate Ciplp21 activity, and recently erythroid Krüppel-like factor 
(EKLF) has been shown to bind directly to Cip1p21 (Rowland and Peeper 2006; Choi, 
Kim et al. 2009; DiFeo, Martignetti et al. 2009; Siatecka, Lohmann et al. 2010). One of 
these proteins, Krüppel-like factor 6 also displays misregulation of alternate splicing in 
a number of cancers (DiFeo, Martignetti et al. 2009). This is of interest given Ciz1’s 
initial discovery due to its interaction with Cip1p21, and research suggesting Ciz1 
stimulates proliferation of oestrogen-stimulated breast cancer cells (Mitsui, Matsumoto 
et al. 1999; den Hollander and Kumar 2006; den Hollander, Rayala et al. 2006). 
Krüppel-like factor 8 is a regulator of cyclin D1, and requires two nuclear localisation 
sequences (NLS) in order to be recruited to the nucleus (Mehta, Lu et al. 2009). One of 
these sequences is located in the N-terminus of the protein, adjacent to the only two SQ 
motifs in the protein. The second NLS is spread across the two C-terminal C2H2 zinc 
fingers. However no sequence homology of the N-terminal NLS is shared with Ciz1 and 
despite the similarities described here, the KLF family contain few SQ/TQ motifs, with  
no report of any connection to the DNA damage response.  
4.5.2.3 Matrin 3 homologous domain 
The other major feature identified in the C-terminus of Ciz1 is a Matrin 3 homologous  
(MH3) domain (Mitsui, Matsumoto et al. 1999). This domain spans residues 782 
through to 835, and has also been found in the C-terminal regions of matrin 3 and 
NP220. It contains unique motifs which have not been observed in any other nuclear 
proteins. Little is known of the function of NP220, however from structural analysis it is 
expected to be a RNA splicing protein (Okumara, Nogami et al. 1998). More is known 
about matrin 3, an abundant nuclear protein which has been shown to interact with 
proteins in the chromatin remodelling, RNA processing, translation, transcription, 
apoptosis, DNA replication and DNA repair pathways (Zeitz, Malyavantham et al. 
2009). Matrin 3 has been found to be phosphorylated in response to DNA damage in 
two separate studies, and interacts with SFPQ and NONO, two proteins which stimulate 
ligation of broken DNA and associate with proteins involved in non-homologous end 
joining (Bladen, Udayakumar et al. 2005; Matsuoka, Ballif et al. 2007; Salton, 
Lerenthal et al. 2010). No detailed dissection of the different regions of matrin 3 has 
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been carried out in connection with its role in the DNA damage response, however the 
similarities suggest that presence of the MH3 domain in Ciz1 may be relevant. 
4.5.3 Implications of LY294002 inhibition of ECiz1 phosphorylation 
Phosphorylation of Ciz1 in the cell free system is affected by both wortmannin and 
LY294002.  In Chapter 3 it was shown that LY294002 does not affect the H2AX 
response, and in fact stimulates its phosphorylation in reactions containing activated 
extracts.  While this amplification of DDR signalling is not expected in a reaction 
lacking nuclei entirely, ATM or ATR-mediated phosphorylation of Ciz1 is not 
consistent with inhibition of SQ/TQ phosphorylation by LY294002. I would therefore 
suggest that Ciz1 is not directly involved in the initial amplification of signalling upon 
detection of DNA damage, and instead propose a model where Ciz1 is involved in the 
pathways slowing DNA synthesised following detection, and is phosphorylated by 
DNA-PK, rather than by ATM or ATR. Given that wortmannin is a broad inhibitor of 
the PIKK family of proteins, and the inconsistencies in the literature over LY294002’s 
precise targets, future study of in vitro phosphorylation of Ciz1’s SQ/TQ motifs could 
benefit from dissection with more specific inhibitors such as KU-55933 (ATM) and 
NU7026 (DNA-PK), which are becoming increasingly commercially available. This 
would confirm identification of the precise PIKK by which Ciz1 is phosphorylated, and 
improve understanding of the pathways in which it is involved. 
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Chapter 5 
CHARACTERISATION OF EXPRESSION OF CIZ1 IN 
RELATION TO THE DNA DAMAGE RESPONSE 
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5.1 Introduction 
In Chapter 4 phosphorylation of SQ/TQ motifs present in mouse ECiz1 was confirmed, 
and traced to the C-terminus of the protein. A number of possible functions for C-
terminal phosphorylation were posited, including modulation of nuclear matrix binding. 
Previous work done in this laboratory shows that Ciz1’s capacity to bind to the nuclear 
matrix is impaired in most cancer cell lines [Sercombe et al, submitted], and that this is 
modulated during development [Munkley, unpublished]. Furthermore preliminary work 
suggested that overexpression of Ciz1 promotes phosphorylation of H2AX [Rahman, 
unpublished]. Here, the effect of DNA damage induction upon Ciz1, and of Ciz1 
overexpression upon the DDR are examined. 
5.2 Aims 
• Do double strand breaks or inhibition of the DNA damage response affect Ciz1 
expression? 
• Do double strand breaks or inhibition of the DNA damage response affect Ciz1 
nuclear matrix binding? 
• Does Ciz1 co-localise with known DNA damage response and cell cycle 
proteins following induction of double strand breaks?  
• Can induction of H2AX phosphorylation in response to Ciz1 overexpression be 
confirmed? 
• Does recombinant Ciz1 affect the response to DNA damage in cell free 
reactions? 
5.3 Experimental Design 
Ciz1 expression and localisation were studied by immunofluorescence in a variety of 
cell lines, by using etoposide and wortmannin to induce or inhibit the DDR, and in the 
cell free system by addition of purified ECiz1 to isolated nuclei and damage-activated 
cell extracts. Etoposide concentrations were initially determined by a combination of 
literature search and titration into cultured NIH3T3 cells to establish what concentration 
was necessary to induce H2AX phosphorylation at levels detectable by Western blot 
 92 
following a two hour incubation. H2AX phosphorylation was examined by 
immunofluorescence and Western blot in NIH3T3 cells overexpressing GFP-tagged 
Ciz1. Examination of expression of Ciz1 mRNA following etoposide treatment was 
carried out by real time PCR (RT-PCR). A panel of healthy and tumour-derived cell 
lines were used for these experiments. While ideally the same cell lines would have 
been used for all experiments, lines varied in their ability to tolerate damage treatments, 
growing time and general vigour. These factors influenced choice of cell lines for 
individual experiments. Limitations of these varying approaches are discussed. 
5.4 Results 
5.4.1 Ciz1 localisation does not alter in response to etoposide or wortmannin 
treatment in two cancer cell lines 
HeLa-S3 and U2OS cells are two cell lines originating from cervical cancer and 
osteosarcoma tumours respectively, and are commonly used in DDR research. U2OS 
cells contain a functional p53 gene capable of inducing an apoptotic response to UV 
exposure (Allan and Fried 1999), whereas no p53 cDNA can be amplified from HeLa-
S3 cells (Jia, Osada et al. 1997). The HeLa-S3 cell line was used to harvest nuclei and 
cytosolic extracts for the cell free experiments and Ciz1 phosphorylation assays 
described in Chapters 2 and 3.  
To examine whether the phosphorylation of Ciz1 observed in vitro by damage-activated 
extracts reflects detectable alterations in endogenous Ciz1, HeLa-S3 and U2OS cells 
were treated for 2 hours with 2µM or 20µM etoposide and washed in 0.1% Triton X-
100 before fluorescent microscopy was used to visualise endogenous Ciz1 and nuclear 
H2AX phosphorylation by immunofluorescence. All cell lines displayed focal H2AX 
phosphorylation in response to double strand break induction, with levels of 
phosphorylation correlating to etoposide concentration. Predictably, when cells were 
exposed to 200µM wortmannin during etoposide treatment H2AX phosphorylation was 
not detected (Figure 5.1a and b). In both HeLa-S3 and U2OS cells Ciz1 displayed the 
focal nuclear pattern previously characterised (Ainscough, Rahman et al. 2007; 
Rahman, Ainscough et al. 2007), but no variation in localisation or intensity of staining 
was detected in response to either etoposide or wortmannin treatment.  
Ciz1 can be seen in the nucleus in two forms - as distinct replication foci, and also as a 
low level background stain. When the focal staining was enhanced digitally and  
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Figure 5.1  Ciz1 does not co-localise with phosphorylated H2AX in
etoposide-treated HeLa-S3 cells or U2OS cells
Immunofluorescence images showing Ciz1 and phosphorylated H2AX in
HeLa-S3 and U2OS cells treated with etoposide and wortmannin.  Cells were
treated for 1.5 hours with either 2µM or 20µM etoposide, in the presence and
absence of 20µM wortmannin. Cells were washed in 0.1% Triton X-100 for
10 seconds, and then rinsed once in PBS before fixation with PFA. Ciz1 was
detected using rabbit Ciz1 1793 polyclonal antibody (green) and anti-rabbit
FITC conjugated secondary antibody. phosphorylated H2AX was detected
using mouse monoclonal anti-phospho H2AX (Ser139) antibody (red) and
anti-mouse Alexa 568 conjugated secondary.  Nuclei were counterstained
with Hoechst 33258 (blue).
a) Ciz1 and phosphorylated H2AX in etoposide and wortmannin-treated
HeLa-S3 cells.
b) Ciz1 and phosphorylated H2AX in etoposide and wortmannin-treated
U2OS cells.
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examined for co-localisation, a small proportion of Ciz1 foci coincided with γH2AX 
foci, but only in cells in which γH2AX had been propagated throughout the majority of 
the nucleus. In instances where γH2AX foci were less numerous, reflecting a lower 
level of DSBs, no co-localisation could be observed. It can be concluded that Ciz1 
replication foci are not the same as γH2AX sites. 
5.4.2 Ciz1’s matrix binding properties may be affected by etoposide treatment in 
healthy cell lines 
The failure of U2OS and HeLa-S3 cells to display any alteration in levels of Ciz1 
expression in response to etoposide treatment in 5.4.1 does not rule out a role for Ciz1 
in the DDR, but does suggest that phosphorylation of Cizl by the PIKKs does not target 
it for degradation. The use of only a detergent wash prior to visualisation could fail to 
reveal transition of protein from soluble or chromatin bound to the nuclear matrix, or 
vice versa. 
Developing upon this first experiment, and looking specifically at Ciz1’s matrix binding 
properties, cells were treated with 20µM etoposide for 2 hours before fluorescent 
microscopy was used to visualise Ciz1 and nuclear H2AX phosphorylation by 
immunofluorescence. Following an initial wash with 0.1% Triton-X100 as in the 
previous experiment, cells were treated with DNase I to strip chromatin and bound 
proteins from nuclei. Mouse NIH3T3 cells, which are derived from non-cancer cell 
lineages, were used in this experiment. Etoposide treatment induced H2AX 
phosphorylation, which was extracted from nuclei when DNase was applied. Multiple 
Ciz1 foci were also displayed, prior to DNase treatment, a small proportion of which 
were retained. However no difference was displayed between Ciz1 levels in control and 
etoposide-treated cells in either sample (Figure 5.2). 
5.4.3 Ciz1 overexpression does not induce H2AX phosphorylation in NIH3T3 cells 
Experiments previously carried out by Faisal Rahman in the Coverley laboratory had 
suggested that Ciz1 overexpression induced H2AX phosphorylation. Two approaches 
were taken to try to confirm this observation. 
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5.4.3.1 Ciz1 overexpression does not induce H2AX phosphorylation 
Amaxa and lipid transfection methods were used to examine levels of H2AX 
phosphorylation following transient transfection of NIH3T3 cells with GFP-Ciz1.  
Initially a Western blot approach was used, however original transfection approaches 
were too harsh, and led to induction of H2AX phosphorylation in both GFP control and 
Ciz1 populations (Figure 5.3a).  The lipid transfection method was adapted to 
incorporate a shorter incubation period of 3 hours in order to reduce damage to the cells. 
To compensate for the resulting decrease in transfection efficiency immunofluorescence 
was used to directly examine H2AX phosphorylation in individual cells.  This method 
clearly showed no increase in H2AX phosphorylation in the GFP-Ciz1 transfected 
population compared to the GFP control, and much lower levels of phosphorylation in 
both transfected populations compared to an etoposide-treated control (Figure 5.3b). 
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5.4.3.2 Addition of 10nM ECiz1 to cell free reactions does not induce H2AX 
phosphorylation 
To confirm this result in the absence of trauma caused to cells by transfection, the effect 
of exposing isolated nuclei to purified ECiz1 protein was examined. In Chapter 3 it was 
confirmed that the DNA damage signalling pathways inducing H2AX phosphorylation 
in these nuclei are intact, and Chapter 4 demonstrated the ability of damage-activated 
extracts to phosphorylate purified ECiz1. Therefore it seemed likely that if increasing 
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the quantity of Ciz1 in cells has an effect on H2AX phosphorylation, it could be 
recapitulated in the system.  
Cell free reactions were carried out in which populations of naive G1 phase nuclei or S 
phase nuclei were incubated in naive S phase extract supplemented with 10nM ECiz1 
for 30 minutes (Figure 5.4a). Reactions were then separated out on a 6.5% gel and 
probed by Western blot for γH2AX and phosphorylated ATM. While base levels of 
γH2AX varied between nuclei, no difference in phosphorylation of either H2AX or 
ATM could be seen in nuclei exposed to ECiz1 (Figure 5.4c).  
5.4.4 Titration of ECiz1 into cell free reactions with etoposide-treated extracts 
inhibits DNA synthesis 
The cell free system allows use of two different measures of response to the DNA 
damage response, the first of which – H2AX phosphorylation – does not appear to be 
affected by Ciz1. As discussed in Chapter 4, inhibition of Ciz1 phosphorylation by 
LY294002 implicates it in the pathways constraining DNA synthesis, rather than in 
initiation and propagation of DNA damage signalling.  
Previous work by the Coverley lab has shown that addition of 1nM ECiz1 to naive cell 
free reactions stimulates initiation of DNA synthesis, while lower and higher levels of 
0.1nM and 10nM have no effect (Coverley, Marr et al. 2005).  Purified ECiz1 was 
titrated into cell free reactions containing S phase naive nuclei and damage-activated 
cytosolic extract at concentrations of 0.1nM, 1nM and 10nM, to examine whether 
addition of exogenous Ciz1 alleviated the drop in DNA synthesis seen in damage-
activated extract (Figure 5.4b). Three replicates with a total of eight paired reactions 
were carried out, and although there was not a consistent level of BdUTP incorporation 
in the presence of ECiz1, only in one instance could any increase be seen, and this was 
negligible at 0.53% (Table 5.1). Of these eight sets of reactions, half displayed a drop in 
BdUTP incorporation of more than twelve percent, two of which were found to be 
highly significant by t-test (p-values of 0.00026 and 2.34xE-5) . 
5.4.5 Effect of etoposide on expression of Ciz1 replication domain and anchor 
domain transcript 
The nucleotide sequences of eukaryotic protein-coding genes contain both introns, 
regions of DNA that are not present in mature mRNA, and exons, regions that are  
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preserved throughout mRNA processing and go on to be translated into amino acids for 
inclusion in the final protein. These exons act as modules, allowing editing of one gene 
to suit a multitude of cellular conditions and fates.  This ability to mix and match 
sections of a protein is known as alternative splicing, and occurs in approximately 70% 
of human genes.  
Ciz1 undergoes extensive alternative splicing, with several exons that are commonly 
altered in cancerous cells (Rahman, Ainscough et al. 2007), and variation in expression 
of the N and C-terminuses of the protein has been observed in a range of human cancers 
[Sercombe et al, submitted] and during cellular differentiation [Jennifer Munkley, 
unpublished]. While no variation in total protein could be seen in response to etoposide 
treatment, it seemed possible that changes in expression of the different regions of the 
protein could be going unreported.  WI38 and U2OS cells were treated for up to 4 hours 
with 20µM etoposide prior to RNA extraction and generation of cDNA. RT-PCR was 
then used to examine levels of replication domain (RD) N-terminus and anchor domain 
(AD) C-terminus Ciz1 using primers for exons 7 and 16 (Figure 5.5a). 
Five timepoints were taken, ranging from untreated cells through to four hours 
etoposide exposure. In WI38 cells a drop in levels of exon 7 mRNA was observed 
following treatment, while levels of exon 16 mRNA rose, peaking one hour after 
etoposide was added and then beginning to drop again (Figure 5.5a). Conversely in 
U2OS cells, levels of both exons decreased following etoposide treatment (Figure 5.5b). 
These opposing trends continued when levels of relative expression of the two exons 
were compared; in WI38 cells etoposide treatment increased levels of exon 16 mRNA 
compared to exon 7 mRNA, while the ratio of exon 16 to exon 7 mRNA fell in U2OS 
cells (Figures 5.5a and b).  
5.4.6 Ciz1 does not co-localise with PCNA, p21 or MDC1 following etoposide 
treatment 
One of the key features of double strand breaks is the rapid recruitment of proteins in 
both the DNA damage detection and repair pathways, forming discrete foci of signalling 
and repair factors (Belyaev 2010; Costes, Chiolo et al. 2010).  As such, a common 
indicator of involvement in the DDR is localisation to these foci, frequently referred to 
as ionising radiation-induced foci (IRIF), following DNA damage. While the 
distribution of foci formed by signaling factors following etoposide treatment will vary 
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from that of IRIF due to both the nature of break induced and the S phase specific 
timing of damage, the content of the foci should not vary. Immunofluorescence was 
used to compare localisation of Ciz1 with that of three known checkpoint and signalling 
proteins, two of which have prior links with Ciz1. 
5.4.6.1 PCNA 
Proliferating cell nuclear antigen (PCNA) is a processivity factor for DNA polymerases 
δ and ε, increasing the rate of incorporation of nucleotides during DNA synthesis 
A 
B 
Figure 5.5 Levels of Ciz1 exon 16 mRNA decrease in WI38 cells following 
etoposide treatment, but increase in the cervical cancer cell line, HeLa-S3 
Real time PCR analysis of Ciz1 expression in WI38 and HeLa-S3 cells following 
addition of 20µM etoposide to culture medium. TaqMan probes located within exon 
7 and exon 16 were used to detect replication domain and anchor domain mRNA 
levels respectively. Relative levels are displayed for each exon, as well as a ratio of  
exon 16 expression compared to exon 7. 
a) Relative and proportional expression of Ciz1 exon 7 and exon 16 mRNA in WI38 
cells over 4 hours following addition of 20µM etoposide to culture medium.  
b) Relative and proportional expression of Ciz1 exon 7 and exon 16 mRNA in HeLa-
S3 cells over 4 hours following addition of 20µM etoposide to culture medium. 
 
A 
B 
 102 
(Bravo, Frank et al. 1987; Burgers 1991). Outside S phase PCNA normally exists as a 
detergent-soluble monomer, however during S phase it forms a detergent-insoluble 
trimer that associates with replication forks, encircling dsDNA and facilitating loading 
of polymerases (Krishna, Kong et al. 1994; Ellison and Stillman 2003). When cycling 
cells are treated with DNA damaging agents, PCNA becomes insolubly bound to 
chromatin, forming foci at the sites of damage (Essers, Theil et al. 2005), and has been 
shown to be involved in nucleotide excision repair (NER), base excision repair (BER) 
and mismatch repair (Nichols and Sancar 1992; Matsumoto, Kim et al. 1994; Umar, 
Buermeyer et al. 1996). These foci do not only form in the presence of single strand 
breaks, but have been shown to occur in an ATM-independent fashion in response to 
DSBs (Balajee and Geard 2001). Localisation of PCNA with Ciz1 has previously been 
observed in a small proportion of cycling cells (Coverley, Marr et al. 2005), therefore 
PCNA was chosen as an initial protein to compare to Ciz1 following etoposide 
treatment. 
HeLa-S3 and NIH3T3 cells were treated with 2µM or 20µM etoposide for up to 3 hours 
prior to washing in 0.1% Triton X-100, before fluorescent microscopy was used to 
visualise Ciz1 and PCNA by immunofluorescence. Co-localisation between Ciz1 and 
PCNA could not be observed under any conditions in either cell line (Figures 5.6a and 
b). 
5.4.6.2 p21 
Ciz1 was initially discovered because of its interaction with p21, binding to the protein 
via a site located somewhere in the 150 amino acids surrounding the first C-terminal 
zinc finger motif. This study also suggested that Ciz1 may mediate localisation of p21, 
speculating that it could transport the protein from the nucleus into the cytoplasm in 
response to DNA damage (Mitsui, Matsumoto et al. 1999). Transcription of p21 is 
stimulated by p53, inhibiting CDK activity and preventing progression from G1 to S 
phase (Bartek and Lukas 2001). H2AX has been shown to stabilise and increase p21 
levels as part of the p53 pathway, diverting the fate of the cell from apoptosis caused by 
degradation of p21 (Allan and Fried 1999; Fragkos, Jurvansuu et al. 2009). P21 is also a 
regulator of PCNA, preventing initiation of DNA synthesis by competitively inhibiting 
interaction with DNA polymerases (Moldovan, Pfander et al. 2007). Co-localisation of 
p21 can also be observed with ATR, phosphorylated ATM, phosphorylated H2AX,  
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Figure 5.6  Ciz1 does not co-localise with PCNA following etoposide treatment
in NIH3T3 and HeLa-S3 cells
Cells were washed in 0.1% Triton X-100 for 10 seconds, and then rinsed once in
PBS before fixation with PFA. Ciz1 was detected using rabbit polyclonal anti-Ciz1
1793 antibody (green) and anti-rabbit FITC conjugated secondary antibody. PCNA
was detected using mouse monoclonal anti-PCNA antibody (red) and anti-mouse
Alexa 568 conjugated secondary.
a) Immunofluorescence images showing Ciz1 and PCNA in NIH3T3 cells. Cells
were treated for up to 3 hours with 20µM etoposide.
b) Immunofluorescence images showing Ciz1 and PCNA in HeLa-S3 cells. Cells
were treated for 2 hours with either 2µM or 20µM etoposide.
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53BP1 and BRCA1 in bystander cells adjacent to cells containing DNA damage 
(Burdak-Rothkamm, Rothkamm et al. 2008). 
NIH3T3 cells were treated with 20µM etoposide for up to 2 hours prior to washing in 
0.1% Triton X-100, before fluorescent microscopy was used to visualise Ciz1 and p21 
by immunofluorescence. No co-localisation could be observed between Ciz1 and p21 
(Figure 5.7). 
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5.4.6.3 MDC1 
Mediator of the DNA damage checkpoint 1 (MDC1) binds to the C-terminus of 
phosphorylated H2AX, recruiting the Mre11-Rad50-Nbs1 complex to sites of double 
strand breaks (Lukas, Melander et al. 2004; Stucki, Clapperton et al. 2005). While this 
interaction between γH2AX and MDC1 is dispensable for the recruitment of DNA 
damage signalling and repair proteins such as 53Bp1 and BRCA2 to lesions, it is vital 
for their formation into stable foci (Celeste, Fernandez-Capetillo et al. 2003; Stewart, 
Wang et al. 2003). MDC1 has also been implicated in non-homologous end joining 
repair of chromosome ends with defective telomeres (Dimitrova and de Lange 2006), 
but this is the extent of its identified involvement in DNA repair so far. Due to its role 
in recruiting and stabilising DDR proteins, MDC1 seemed a good target to compare 
against Ciz1. As the MDC1 antibody used was raised against rabbit, a mouse 
monoclonal antibody raised against the C-terminus of Ciz1 was used to visualise Ciz1 
expression. 
D3T3 cells were treated with 20µM etoposide for 2 hours prior to washing in 0.1% 
Triton X-100, before fluorescent microscopy was used to visualise Ciz1 and MDC1 by 
immunofluorescence. Following etoposide-treatment no obvious change in either 
protein could be seen, and no co-localisation was observed between the two (Figure 
5.8).  
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5.5 Discussion 
In this chapter both live cells, and the cell free system described in chapter 3 were used 
to ask two main questions – what is the effect of DSB induction upon Ciz1 expression 
and transcription, and can a measurable effect of excess Ciz1 upon DNA damage 
signalling be observed? From these experiments we can draw the following 
conclusions:  
• Overexpression of Ciz1 in intact cells and addition of excess ECiz1 to isolated 
nuclei in cell free reactions does not induce H2AX phosphorylation; however 
supplementation of cell free reactions containing damage-activated extract with 
ECiz1 further inhibits DNA synthesis in naïve nuclei. 
• No change can be observed in overall Ciz1 protein levels or in its nuclear matrix 
binding following etoposide treatment in either a healthy or tumour-derived cell 
line. 
• Ciz1 does not co-localise with PCNA, p21 or MDC1 in response to etoposide 
treatment. 
• Ciz1 transcript expression responds to etoposide treatment: exon 7 mRNA 
dropped in both WI38 and U2OS cells. In the normal cell line this was 
accompanied by a rise in exon 16 transcript levels, whereas in the tumour-
derived line exon 16 transcript fell. 
While these conclusions do not provide a simple explanation for Ciz1’s role in the DNA 
damage response, they do support the PIKK-dependent phosphorylation of Ciz1 
observed in Chapter 4, and further implicate the C-terminal domain of Ciz1. As such a 
number of avenues are opened up for discussion and speculation. 
5.5.1 Ciz1 is likely to be a non-IRIF-associated DDR protein  
The evidence collected so far – Ciz1’s failure to promote γH2AX foci, associate with 
known DDR proteins, or to display any change in spatial location, levels or nuclear 
binding following etoposide treatment – rule out a role in propagation of initial DDR 
signalling fairly conclusively. It is important to note that while the formation of 
damage-induced γH2AX foci is a major method by which DNA damage is detected and 
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repaired, there are a number of proteins that do not form discernable foci, including 
Chk1, Chk2, p53, Cdc25a, DNA-PK and SMC1 (Bekker-Jensen, Lukas et al. 2006), and 
that recruitment to IRIF is neither an essential, nor a defining feature of DDR proteins. 
Furthermore, while phosphorylation of SQ/TQ motifs is indicative of involvement in 
the DDR, it does not always affect recruitment to damage foci - this is independent of 
SCD phosphorylation in BRCA1 (Cortez, Wang et al. 1999; Kitagawa, Bakkenist et al. 
2004). In short, while the failure of Ciz1 to associate with IRIF makes involvement in 
early stages of DDR signalling unlikely, it does not rule out involvement in the response 
altogether. Given the PIKK-dependent phosphorylation of Ciz1 observed in response to 
DDR induction both in vitro here and in intact cells in the Matsuoka study (Matsuoka, 
Ballif et al. 2007), combined with the changes in mRNA expression seen following 
etoposide treatment, it seems likely that Ciz1 may instead be involved in the response at 
a different level. 
5.5.2 Non-IRIF-associated proteins have a number of known roles in the DDR 
If Ciz1 is a non-IRIF-associated DNA damage response protein, the question is raised 
of what role it might play. The roles of known non-IRIF-associated proteins will be 
discussed briefly.   
5.5.2.1 Regulation of cell cycle checkpoints  
Two key non-IRIF-associated proteins are the checkpoint kinases, Chk1 and Chk2. 
Chk1 and Chk2 are activated by ATR and ATM respectively following DNA damage, 
and go on to play a variety of roles in the response, but do not form cytologically 
discernible foci. Isoforms of Cdc25, a phosphatase required for successful transition 
between the G1 and S phases of the cell cycle, are phosphorylated by Chk1 and Chk2 in 
response to DNA damage either inactivating them, inducing export from the nucleus or 
inducing degradation of the protein (Furnari, Blasina et al. 1999; Lopez-Girona, Furnari 
et al. 1999; Xiao, Chen et al. 2003). Again, despite its important role in the DDR, no 
accumulation of Cdc25 can be seen at DSBs. Another pair of non-IRIF-associated 
proteins, DNA-PK and its partner Ku70 were implicated in DSB-induced inhibition of 
DNA synthesis in Chapter 3. 
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5.5.2.2 Transcription of DSB-induced genes and induction of apoptosis 
E2F1 is a member of the E2F family of transcription factors, which regulate genes 
involved in cell cycle control. Once activated by DNA damage, both Chk1 and Chk2 
phosphorylate E2F1 and its partner pRB (Stevens, Smith et al. 2003; Urist, Tanaka et al. 
2004; Inoue, Kitagawa et al. 2007), with E2F1 also known to be a substrate of DNA-PK 
(Watanabe, Shinohara et al. 2003). In addition to regulating expression of genes such as 
cyclin E, p107, CDC6 and ribonucleotide reductase, which are required for successful 
transition between phases of the cell cycle, E2F1 has been shown to stimulate 
transcription of ATM, Chk1, Apaf1, p73 and ARF, which are involved in DNA damage 
detection, repair and apoptosis (Polager, Kalma et al. 2002; Stevens and La Thangue 
2004). Chk1 and Chk2 also influence the p53-mediated apoptotic pathway, by 
phosphorylating both p53 (another protein which does not localise in response to DNA 
damage) and other components of the pathway (Stracker, Usui et al. 2009). 
5.5.2.3 Chromatin modification and DNA repair 
SMC1 and SMC3 are two components of the cohesin complex, which maintains sister 
chromatid cohesion and is required for successful repair of double strand breaks 
(Atienza, Roth et al. 2005). Damage-induced phosphorylation of SMC1 and SMC3 are 
also involved in checkpoint signalling (Kim, Xu et al. 2002; Yazdi, Wang et al. 2002; 
Luo, Li et al. 2008), but while modification of SMC1 is only seen in the vicinity of 
DNA lesions, the protein can be found across the entire nucleus, with no overall shift in 
localisation (Bekker-Jensen, Lukas et al. 2006). Additionally, activated Chk1 modifies 
chromatin structure by cessation of normal phosphorylation of histone H3, providing a 
physical block to transcription of cell cycle modulators such as cyclin B1 and CDK1 by 
preventing interaction of GCN5 with their promoter elements (Shimada and Nakanishi 
2008; Shimada, Niida et al. 2008). 
In summary, non-IRIF-associated DDR proteins tend to either be effectors playing roles 
in cell cycle arrest or transcription, or mediators that exploit this lack of localisation to 
allow them to connect downstream signalling molecules at the site of DSBs with 
effectors throughout the entire nucleus. Like Cdc25, p21, and the CDK and cyclin 
families, Ciz1 already possesses a well-characterised role in cell cycle progression, and 
inhibition of its phosphorylation by LY294002 implies a connection to DNA-PK. I 
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would therefore suggest that Ciz1 may play a role in control of cell cycle during the 
DDR, and shall go on to explore this idea in greater depth in Chapter 6. 
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Chapter 6 
GENERAL DISCUSSION 
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The aim of this thesis was to investigate Ciz1’s involvement in the DDR, first by 
establishing whether it is phosphorylated by the PIKKs in response to etoposide 
treatment, and then by attempting to identify a role for the protein within the DDR 
process. Several approaches were taken, one of which, the development of a cell free 
approach to study the DNA damage response, has had significant implications in its 
own right. As such this chapter will cover two main elements: applications of the new 
developments to this system and speculation upon Ciz1’s role in the DDR. 
6.1 Development of the cell free system as a tool to study the DDR 
Chapter 3 dealt in detail with adaptation and characterisation of a cell free system 
previously used to carry out studies of DNA replication initiation and elongation to 
permit study of the events resulting from etoposide-induced DNA damage. When 
reconstituted in vitro, the PIKK-dependent signalling that takes place as a consequence 
of DSB formation can be isolated from and manipulated separately to DNA damage 
itself and also isolated from the process of DNA repair. Soluble factors present in 
damage-activated extracts recreate both G1/S and intra-S phase checkpoints, impinging 
on initiation and elongation of DNA synthesis respectively. Finally, upstream events 
that signal the activation of soluble components of the DDR have also been 
reconstituted in vitro. Two uses of the system have been illustrated in Chapters 3 and 4; 
firstly for study and dissection of the DDR signalling pathways, and secondly as a 
screening tool to assess potential inhibitors of the PIKKs and other molecules in these 
pathways. 
6.1.1 Use of the cell free system to draw biological conclusions about the DDR 
Use of the cell free system to study DDR pathways can be divided into two main 
examples. These consist of the use of the two biological markers to draw conclusions 
about the effect of different inhibitors upon the two main pathways that constitute the 
DDR, and use of cell free extracts to study damage-induced phosphorylation of Ciz1. 
6.1.1.1 Contrasting biological markers allow dissection of the different pathways of the 
DDR 
In Chapter 3 use of two PIKK inhibitors with different substrate specificities 
demonstrated the systems capacity to be used to draw biological conclusions. While 
wortmannin and LY294002 both removed the block on DNA synthesis imposed by 
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activated extract they differed in their impact on H2AX phosphorylation. Wortmannin 
caused a reduction in phosphorylation of H2AX, but treatment with LY24002 led to an 
increase over that imposed by activated extract alone. Thus, phosphorylation of H2AX 
is uncoupled from ongoing DNA synthesis. This is consistent with published 
observations, which suggest that the DDR chiefly slows DNA synthesis during S phase 
by inhibition of origin firing (Larner, Lee et al. 1999), with ongoing synthesis being 
routinely observed at a low rate in damage-activated extracts used in Chapter 3.  
Furthermore, by examining the effect of the two inhibitors upon H2AX 
phosphorylation, it was possible to clarify conflicting results that had been seen when 
using LY294002 as part of previous in vitro and cellular studies (Cheatham, Vlahos et 
al. 1994; Stiff, O'Driscoll et al. 2004). From observations here it seems likely that while 
LY294002 interacts with purified ATM in vitro, in a cellular context it does not affect 
ATM signalling, possibly due to altered folding and modification of protein produced 
by bacterial purification. Lastly the preservation of H2AX phosphorylation seen with 
LY24002 suggests that DNA damage detection is uncoupled from inhibition of DNA 
synthesis, and that DNA-PK helps to slow DNA replication in damaged cells in a 
manner that is independent of ATM and ATR. 
6.1.1.2 Use of soluble DDR factors to phosphorylate SQ/TQ motifs 
Chapter 4 then goes on to document use of the cell free system as an assay for 
phosphorylated SQ/TQ motifs, allowing identification of PIKK substrates. This assay 
possesses the advantage that it permits study of a specific protein rather than the 
somewhat scattershot approach used in the mass spectrometry assays described in 
Chapter 4 (Matsuoka, Ballif et al. 2007; Stokes, Rush et al. 2007). Additionally, this 
method only requires synthesis of the target protein and not of phosphorylated ATM 
and ATR, and the use of damage-activated cytosolic extract is more representative of an 
in vivo environment than purified protein interaction assays. 
6.1.2 Potential for the cell free system to be used as an assay for DDR inhibitors 
As demonstrated by the use of wortmannin and LY294002 in Chapter 3, the cell free 
system also serves as an assay for potential DDR inhibitors. In recognition of the 
advantages provided by the cell free system, a patent has been submitted by the 
University of York for the technology (Patent No. GB0903373.9), and funding has been 
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allocated by the University Research Innovation Office’s Strategic Initiative Fund for 
further development of the system as a high throughput assay. 
6.1.2.1 Need for targeted cancer treatments  
In the past decade there has been a switch in focus to development of targeted therapies 
that exploit specific differences between cancer and healthy cells, driven by the severe 
side effects of conventional chemotherapies and radiotherapies. The number of 
documented genetic and epigenetic differences is escalating as a result of intensive 
research (Collins and Barker 2007), offering a raft of new potential therapeutic targets. 
With detailed and specific knowledge of specific pathways and players comes the 
opportunity to design very specific chemical inhibitors. Structure-based drug design 
takes key altered proteins, and uses knowledge of their crystal structure to design 
inhibitors that can specifically target tumour cells. Protein kinases are a classic example 
of this, as they are easily purified in quantity, involved in many critical pathways, and 
their targets are frequently mutated in cancers (Eglen and Reisine 2009). A number of 
inhibitors of tyrosine receptor kinases have been approved for clinical use, including 
tarceva and iressa, and cyclin dependent kinase inhibitors such as alvocidib and 
seliciclib have been entered into phase II and III trials (Hidalgo, Siu et al. 2001; 
Wakeling, Guy et al. 2002; Shapiro 2006). 
6.1.2.2 PIKKs are a good target for selective treatments 
One class of protein kinases which has been identified as holding therapeutic potential, 
is the PIKK family. Blocking PIKKs increases sensitivity of cells to radiation, 
increasing effectiveness of radiotherapy (McKenna and Muschel 2003), and is likely to 
increase the efficacy of chemotherapies that act by creating DNA damage. While 
wortmannin and LY294002 are useful research tools, they are not ideal for clinical 
purposes as they show effects on other kinases and have concentration and stability 
issues.  
Through high throughput screening a number of classes of PIKK inhibitors have been 
discovered and are in clinical trials. These efforts have chiefly focused on the PI3K-
AKT-MTOR pathway, due to its frequent deregulation in tumour cells and role in 
regulating cell growth and survival (Workman, Clarke et al. 2010). However its 
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involvement in a range of pathways from glucose metabolism to haematopoietic stem 
cell regulation means that chronic inhibition could lead to serious side effects (Zhang, 
Grindley et al. 2006; Sopasakis, Liu et al. 2010). The more specialised roles of the 
PIKKs ATM and ATR present a more focused avenue for drug discovery, however as 
we learn more about their role in regulating the DNA replication fork (Shechter, 
Costanzo et al. 2004) it is becoming evident that their inhibition may have undesirable 
effects. 
6.1.2.3 Benefits of the cell free system as an assay 
Progress of research into the oncogenome over the past decade has been facilitated by 
the availability of high-throughput technologies such as fluorescence in situ 
hybridisation, high-throughput DNA sequencing and chromatin immunoprecipitation 
microarrays. In order to exploit the role of protein kinases in cancer, a number of gene- 
focused bio-assays have been developed to look for substrates and downstream 
signalling partners (Eglen and Reisine 2009). This has led to generation of cell-based 
assays, such as bioluminescence resonance energy transfer and protein fragment-
complementation which are also able to screen libraries of inhibitors for specific protein 
kinases (Moll, Prinz et al. 2006; Prinz, Diskar et al. 2006; Stefan, Aquin et al. 2007). 
These assays are useful tools, but have the drawback that they require tagging of the 
target kinase, and only permit study of an individual, rather than an entire pathway. 
Development of new high throughput technologies, for both genome & proteome 
characterisation and for drug discovery, is of great importance in understanding and 
treating cancer. This cell free approach offers a highly focused biological assay, with 
multiple fluorescent outputs, that is amenable to high-throughput format. Furthermore, 
in addition to reconstituting and isolating the role of known DDR players such as ATM 
and ATR, it also offers access to as yet unidentified players whose inhibition could have 
potent and selective effects on the cell’s response to DNA damage.  
6.2 Involvement of Ciz1 in the DDR 
In Chapters 4 and 5, variations of the properties of Ciz1 in response to DSB induction 
were studied, both within the cell free system and in intact cells. These experiments 
gave rise to the following conclusions: 
• Ciz1 is phosphorylated in response to DDR activation 
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• Ciz1 phosphorylation is inhibited by LY294002 treatment, and is therefore 
likely to be DNA PK-induced, and part of the pathways leading to inhibition of 
DNA synthesis 
• Ciz1 is not recruited to IRIF 
• Nuclear matrix binding of Ciz1 is not altered by DSB induction 
• Ciz1 does not induce ATM-mediated early DDR signalling, or stimulate H2AX 
phosphorylation 
• Expression of Ciz1 C-terminal mRNA increases following DSB induction in a 
healthy human lung fibroblast cell line. Contrastingly, C-terminal mRNA levels 
fall in a human osteosarcoma cell line under the same conditions 
Given these results and pre-existing knowledge about Ciz1, I shall go on to speculate 
upon Ciz1’s role in the DDR and how it can be tested. This section will focus upon two 
main questions: how could DDR activation affect spatial organisation of Ciz1 in the 
nucleus, and how might Ciz1’s existing role in control of DNA replication initiation tie 
in with the DDR? 
6.2.1 Spatial organisation of DDR proteins - where can we place Ciz1? 
Proteins involved in the DDR can be divided into two main classes - proteins present in 
a fixed format throughout chromatin which are only activated following modification 
induced by proximity to a lesion, and proteins that alter location in response to damage 
(Bekker-Jensen, Lukas et al. 2006). Those proteins that relocalise in response to DNA 
damage can be assigned three main targets: 
• DSB-flanking chromatin (MDC1, MRN complex, 53BP1, BRCA1, ATM). 
These proteins are signal amplification and recruitment factors, forming classic 
IRIF. IRIF can cover up to a megabase, and are visible by fluorescent 
microscopy (Bekker-Jensen, Lukas et al. 2006).  
• ssDNA containing microcompartments (ATR, RPA, Rad51, Rad52, BRCA2, 
FANCD2). These proteins are recruited to repair centres for individual breaks 
and their foci are visible by fluorescent microscopy. 
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• Unprocessed DSB and partially processed DSB intermediates, suggesting direct 
interaction with DNA ends (DNA-PK, Ku70, SMC1/3 cohesin containing 
complex). These foci are generally outside the resolution achievable by 
fluorescent microscopy, unless massive damage outside the scope of normal 
physiological conditions is inflicted. 
As recruitment of Ciz1 to IRIF at DSB-flanking chromatin has already been ruled out, it 
seems likely that Ciz1 either falls either into the first class of nuclear-bound locally 
activated proteins, or that similar to DNA-PK, it is recruited to microcompartments at 
the sites of unprocessed breaks which are beyond the resolution of light microscopy. 
Should it be that Ciz1 localisation is unaffected by DNA damage, but that SQ/TQ 
modification is induced by nearby breaks, a phospho-specific antibody for Ciz1 would 
be required to detect this phosphorylation. If it is instead the case that Ciz1 localisation 
does change but at a lower resolution than can be visualised, it is possible that 
application of a dose of etoposide sufficient to induce massive disruption of DNA could 
result in visible co-localisation of Ciz1 with DNA-PK. In this instance the methods used 
by Bekker-Jensen et al to induce DSBs by intense laser irradiation could also reveal 
Ciz1 localisation at the sites of unprocessed breaks, with the advantage that damage is 
constrained to a limited section of the nucleus, rather than spread throughout it as with 
use of chemical or ionising radiation-induced damage. 
6.2.2 Ciz1 may inhibit DNA synthesis in response to DNA damage via its role in 
controlling DNA replication initiation 
At the end of chapter 5 I suggested that Ciz1 might play a role in cell cycle control 
during the DNA damage response. This idea is supported by several pieces of evidence 
- firstly inhibition of its phosphorylation in damage-activated extract supplemented with 
LY294002. As discussed earlier in this chapter and chapter 3, LY294002 alleviates 
inhibition of DNA synthesis in damage-activated extracts without reducing H2AX 
phosphorylation. It seems likely that proteins affected by LY294002 contribute to 
restraint of DNA replication. It is known that formation of DSBs mainly inhibits DNA 
synthesis by inducing a drop in origin firing throughout S phase (Larner, Lee et al. 
1999). Ciz1 has a characterised role in the events leading up to licensing of replication 
origins that may well contribute to this decrease. 
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6.2.2.1 Sequential activation of cyclins E and A plays an important role in initiation of 
DNA replication 
Control of DNA initiation and transition from G1 to S phase is controlled in part by 
cyclin E and cyclin A, in combination with their protein kinase partner CDK2. In 
addition to controlling transcription of S phase proteins, cyclin E facilitates MCM 
loading during pre-RC assembly and in concert with CDK2 promotes licensing of DNA 
replication origins (Jackson, Chevalier et al. 1995; Coverley, Laman et al. 2002; Geng, 
Lee et al. 2007; Chuang, Teixeira et al. 2009). Cyclin A-CDK2 activates existing pre-
RC complexes, and stimulates DNA synthesis elongation, promoting S phase 
(Coverley, Laman et al. 2002; Yam, Fung et al. 2002; Woo and Poon 2003). Cyclin A-
CDK2 also phosphorylates CDC6, leading to its export from the nucleus to cytoplasm, 
preventing formation of new pre-RC and thereby avoiding rereplication (Petersen, 
Lukas et al. 1999). CDK2-dependent functions of cyclins E and A rely upon the 
interaction with CDK2 causing CDK2 to enter an active conformation, exposing the 
active site of the protein to ATP. With these important roles in pre-RC assembly and 
activation and prevention of rereplication, cyclin E and cyclin A must bind to CDK2 in 
the correct order for DNA replication to be carried out properly.  
6.2.2.2 Ciz1 is a platform for sequential cyclin E and A loading onto the nuclear matrix 
Cyclins interact with inhibitors, activators and substrates using binding sequences 
known as Cy motifs (Wohlschlegel, Dwyer et al. 2001). Ciz1 contains five Cy motifs, 
three within its replication domain, and two in its anchor domain (Figure 6.1a). While 
little is known of the function of the C-terminal Cy motifs (one of which is located just 
after the third C2H2 zinc finger) the interactions of the N-terminal Cy motifs with 
cyclins E and A have been characterised by this laboratory. Via these N-terminal motifs, 
Ciz1 binds cyclins E and A, and works in cooperation with cyclin A/CDK2 to promote 
DNA replication initiation (Copeland, Sercombe et al. 2010). Cyclin E binds to Ciz1 at 
Cy-ii, but can be displaced by cyclin A, which binds to both Cy-ii and Cy-iii. 
Immobilisation of cyclin E upon the nuclear matrix is independent of Ciz1, but 
immobilisation of cyclin A is disrupted by depletion of Ciz1.  
Given the temporally distinct nature of cyclin E and A expression (Sherr 1995) 
Copeland proposes a model in which Ciz1 becomes bound to cyclin E during pre-RC 
assembly during late G1 phase, before recruitment of cyclin A to Ciz1 displaces cyclin 
E, regulating their sequential roles at pre-RC complexes (Figure 6.1b). While the C- 
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terminal region of the protein is not required for interaction with either cyclin, this 
model also suggests that the matrix-binding properties of Ciz1 may support delivery of 
cyclin A to replication factories. Once bound to Ciz1 at these sites, cyclin A-CDK2 is 
able to locally promote initiation of DNA replication. This model is supported by 
observation of co-localisation between Ciz1 and cyclin A in cycling cells [Nikki 
Copeland; unpublished], and describes a Ciz1-dependent step in origin licensing and 
firing which could be modulated in response to DNA damage.  
6.2.3 Three models for Ciz1-mediated inhibition of origin firing 
DNA PK is a member of the PIKK family, and forms a trimer with two Ku units in 
presence of DNA (Dvir, Peterson et al. 1992; Downs and Jackson 2004). 
Autophosphorylation of DNA-PK in response to ionising radiation is dependent both on 
Ku and upon MDC1, and leads to co-localisation with γH2AX and 53BP1 (Chan, Chen 
et al. 2002; Lou, Chen et al. 2004). While ATM and DNA-PK both phosphorylate 
H2AX in a redundant fashion following exposure to ionising radiation, DNA-PK is not 
capable of phosphorylating downstream signalling proteins such as Chk2, NBS1, CtIP, 
BLM, and p53 (Stiff, O'Driscoll et al. 2004). Tellingly, DNA-PK is preferentially 
autophosphorylated in response to replication-associated DSBs as opposed to ionising 
radiation induced breaks during S phase (Chen, Chan et al. 2005). As etoposide induces 
DSBs by stalling the replication fork, DNA-PK should be active in both the damage-
activated extract and in vivo experiments described here (Li and Liu 2001). As 
discussed in chapter 3, it seems likely that DNA-PK is the LY294002-inhibited 
component of the DDR responsible for restraining DNA synthesis in the cell free 
system, and that it is also the protein responsible for phosphorylation of ECiz1 in 
damage-activated cytosolic extract observed in chapter 4. Based upon the results in this 
thesis, I propose a model in which DNA-PK phosphorylates Ciz1 in response to double 
strand break signalling, which then causes Ciz1 to modulate origin firing via its 
interactions with cyclins E and A, and CDK2. As yet there is little evidence as to how 
Ciz1 would do this, but existing knowledge of its function gives us three possible 
explanations that could be tested (Figure 6.1c). 
6.2.3.1 Preferential recruitment of C-terminal fragments to unfired origins? 
In chapter 5, RT-PCR data suggested a rise in expression of Ciz1 C-terminal mRNA 
following etoposide treatment in a normal cell line. This uncoupled expression of 
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different regions of Ciz1 mRNA is not unusual - there are a large number of splice 
variants of the protein, and variation in N and C-terminal expression has been 
previously observed in several biological contexts. Heather Sercombe found uncoupled 
expression of the two ends of Ciz1 in a range of tumour cells, with transcription of C-
terminal exons exceeding N-terminal mRNA in stage I through to III tumours, but with 
the balance reversing to favour the replication domain of Ciz1 in metastatised tissue 
[Sercombe et al, submitted]. Similar uncoupling has also been seen in differentiating 
tissue, with increased expression of C-terminal mRNA as human urothelial cells are 
stimulated to differentiate [Jennifer Munkley, unpublished].  
The 1793 antibody commonly used to study Ciz1 expression is specific to the N-
terminus of the protein, and antibodies targeting the C-terminus have only recently been 
developed. There is therefore very limited knowledge about levels of expression and 
localisation of the nuclear matrix binding region at the protein level. However 
overexpression of recombinant GFP-tagged C-terminus Ciz1 has shown that it 
competitively disrupts nuclear binding of full length endogenous Ciz1, and that this 
affects assembly of pre-RC (Sercombe et al, submitted). Newly produced Ciz1 is 
recruited to replication factories during early-mid G1 phase and is required for 
progression into S phase (Coverley, Marr et al. 2005; Ainscough, Rahman et al. 2007). 
This raises the question of whether the observed increase in C-terminal mRNA could 
represent an increase in translated splice variants with a dysfunctional N-terminal region 
that might preferentially be recruited during G1 phase. Lacking the N-terminal Cy 
motifs shown to be required for interaction with cyclins E and A, cyclin exchange 
would be unable to occur, and cyclin A/CDK2 would be unable to stimulate DNA 
synthesis initiation (Figure 6.1c). While no decrease was seen in nuclear matrix-bound 
N-terminus Ciz1 following etoposide treatment, this is not necessarily incompatible 
with C-terminus recruitment. This model could be tested by comparison of cyclin A co-
localisation with Ciz1 N & C-terminal regions by immunofluorescence following 
etoposide treatment. 
6.2.3.2 Ciz1 DNA replication activity is modulated by CDK2 phosphorylation sites 
The ability of Ciz1 to stimulate DNA replication initiation in vitro has already been 
mentioned. In the cell free system, this effect peaks at a concentration of 1nM, with any 
increase causing numbers of initiating nuclei to fall. In addition to Cy motifs, Ciz1 
contains a number of possible CDK-phosphorylation sites, through which members of 
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the CDK family commonly phosphorylate substrates (Figure 6.1) (Endicott, Noble et al. 
1999). When one of these sites, threonine 191/2, is replaced with two alanine residues 
rendering it unable to be phosphorylated, initiation does not fall when the threshold 
level of 1nM Ciz1 is exceeded, but remains at an increased level (Coverley, Marr et al. 
2005). Modulation of Ciz1’s capacity to stimulate initiation can also be achieved by 
inactivating the CDK phosphorylation site threonine 293 (Coverley, Marr et al. 2005). 
If phosphorylation of these sites by CDK2 is required for promotion of initiation by 
Ciz1 in concert with cyclin A/CDK2, it is possible that phosphorylation of nearby 
SQ/TQ motifs (Figure 6.1a) could effect conformational changes within Ciz1 that 
prevent access to CDK phosphorylation sites (Figure 6.1c).  
This model could potentially be tested by titrating purified Ciz1 phosphorylated in vitro 
by damage-activated extract into cell free initiation assay reactions, and asking whether 
the initiation profile mimics those seen using CDK phosphorylation site mutants. 
Alternatively, point mutation could be used to edit the SQ/TQ motifs adjacent to CDK 
phosphorylation sites so that they are either constitutively phosphorylated or incapable 
of phosphorylation, and these mutants used to generate initiation profiles. Neither 
method would give evidence for a direct link between CDK2 and Ciz1, but could 
provide an indication whether this avenue is worth investigating further. 
6.2.3.3 Stabilisation of cyclin E-Ciz1 interactions following DNA damage induction? 
One clear method of delaying initiation would be if phosphorylation of SQ/TQ motifs 
within Ciz1 stabilised its binding to cyclin E, leading to retention of the protein at pre-
replication complexes (Figure 6.3c). This could be effected either by direct interaction 
with cyclin E, or by conformational change inactivating the Cy-iii motif which is 
required by cyclin A, but not cyclin E, to bind to Ciz1 (Copeland, Sercombe et al. 
2010). In addition to altering rates of DNA synthesis stabilisation of cyclin E at 
replication factories could also provide positive feedback, promoting earlier stages of 
DDR signalling. Cyclin A has been shown to act as a negative regulator of CDC6 as 
well as promoting its export from the nucleus (Petersen, Lukas et al. 1999; Coverley, 
Laman et al. 2002). CDC6 is required for Chk1 activation (Clay-Farrace, Pelizon et al. 
2003; Oehlmann, Score et al. 2004), so disruption of cyclin A/CDK2 activity by 
competition for CDK2 by cyclin E could help sustain Chk1 signalling.  
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Again, this model can be tested using immunofluorescence techniques. If cyclin E and 
Ciz1 are stabilised at replication factories, co-localisation of the two should be seen as 
with cyclin A and Ciz1. If DSB induction results in a stabilisation of cyclin E and Ciz1 
interaction, then such a co-localisation should be prolonged into S phase following 
etoposide treatment. The cell free system also provides the opportunity to use damage-
activated extracts to create phosphorylated Ciz1 in vitro, which could then be used to 
ask whether sequential addition of cyclin E and cyclin A still shows the displacement of 
cyclin E characterised by Copeland’s study, or whether cyclin E maintains a stable 
interaction with Ciz1. 
6.2.4 Conclusions 
While it is difficult to choose one specific model for Ciz1’s involvement in the DDR 
without further experimentation, current literature does provide some insight as to 
which might be correct.  Research into the response to UV induced DNA damage, 
shows that exposure has both increased transcription of cyclin E and stabilised the 
protein during S phase (Carcagno, Ogara et al. 2009; Lu, Liu et al. 2009). Furthermore, 
PIKK-dependent artemis-mediated degradation of cyclin E is known to contribute to 
recovery from the S phase checkpoint (Wang, Zhang et al. 2009). When the amino acid 
residues responsible for this degradation were inactivated by point mutation, lower 
levels of cyclin A bound to CDK2 could be retrieved by immunoprecipitation. Given 
Ciz1’s role in mediating cyclin exchange, this evidence provides strong support for a 
model in which PIKK-dependent phosphorylation of SQ/TQ leads to stabilisation of 
cyclin E upon the pre-replication complex, preventing initiation of DNA synthesis. 
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ABBREVIATIONS 
53BP1  Tumour protein p53 binding protein 1 
AD  Anchor domain 
Apaf1  Apoptotic peptidase activating factor 1 
AQ  Alanine glutamine 
ATM  Ataxia telangectasia mutated 
ATP  Adenosine triphosphate 
ATR  Ataxia telangectasia mutated related 
ATRIP  ATR interacting protein 
BdUTP  Biotinylated dUTP 
BER  Base excision repair 
BLM  Bloom syndrome protein 
BRCA1  Breast cancer 1 
BRCA2  Breast cancer 2 
BRCT  Breast cancer 1 C-terminal domain 
BSA  Bovine serum albumin 
C2H2  Cys 2 His 2 zinc finger 
CAPS  3-(Cyclohexylamino)-1-propanesulfonic acid 
Cdc25  Cell division cycle 25 
CDC6  Cell division cycle 6 
CDK  Cyclin dependent kinase 
CDK1  Cyclin dependent kinase 1 
CDK2  Cyclin dependent kinase 2 
cDNA  Complementary DNA 
Chk1  Checkpoint kinase 1 
Chk2  Checkpoint kinase 2 
Ciz1  p21 cip1-interacting zinc finger protein 
CPK  Creatine phosphokinase 
CREB  cAMP response element-binding protein 
CSK buffer Cytoskeletal buffer 
Ct  Cycle threshold 
CtBP  C-terminal binding protein 
CtIP  CtBP-interacting protein 
CTP  Cytidine triphosphate 
Cy  Cyclin binding motif 
dATP  Deoxyadenosine triphosphate 
dCTP  Deoxycytidine triphosphate 
DDR  DNA damage response 
dGTP  Deoxyguanosine triphosphate 
DLC1  Dynein light chain 1  
DMEM  Dulbecco’s modified eagle medium 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
DNA-PK DNA-dependent protein kinase 
dNTP  Deoxyribonucleotide triphosphate 
DSB  Double strand break 
DTT  Dithiothreitol 
dTTP  Deoxythymidine triphosphate 
E2F1  E2F transcription factor 1 
ECiz1  Embryonic Ciz1 
EDTA  Ethylenediaminetetraacetic acid 
EGTA  Ethylene glycol tetraacetic acid 
EKLF  Erythroid Krüppel-like Factor  
ERE  Estrogen response element 
ERH  Enhancer of rudimentary homolog 
Erα  Estrogen receptor alpha 
EST  Expressed sequence tag 
FANCD2 Fanconi anemia group D2 protein 
FCS  Foetal calf serum 
 126 
FHA  Forkhead-associated domain 
FITC  Fluorescein isothiocyanate 
G1 phase Growth phase 1 
G2 phase Growth phase 2 
GFP  Green fluorescent protein 
γH2AX  Phosphorylated histone H2AX 
GST  Glutathione S-transferase 
GTP  Guanosine triphosphate 
H2AX  Histone H2A variant x 
HR  Homologous recombination 
IC50  Half maximal inhibitory concentration 
ICL  Interstrand crosslink 
IPTG  Isopropyl β-D-1-thiogalactopyranoside 
IR  Ionising radiation 
IRIF  Ionising radiation induced foci 
KLF  Krüppel-like factor 
Ku70  Ku autoantigen protein p70 
LB  Luria-Bertani medium 
M  Mitosis 
MCM  Mini chromosome maintenance protein 
MDC1  Mediator of DNA damage checkpoint protein 1 
MH3  Matrin 3 homologous domain 
MMR  Mismatch repair 
MRN  Mre11-Rad50-Nbs1 complex 
mRNA  Messenger RNA 
MTOR  Mammalian target of rapamycin 
NER  Nucleotide excision repair 
NHEJ  Non-homologous end joining 
NLS  Nuclear localisation signal 
p21  Cyclin-dependent kinase inhibitor 1 
p53  Tumour protein 53 
PAGE  Polyacrylamide gel electrophoresis 
PBS  Phosphate buffered saline 
PCNA  Proliferating cell nuclear antigen 
PCR  Polymerase chain reaction 
PFA  Paraformaldehyde 
PIKK  Phosphoinositide-3-kinase-related protein kinase 
PMSF  Phenylmethanesulfonylfluoride 
pRB  Retinoblastoma protein 
pre-RC  Pre-replication complex 
RD  Replication domain 
RNA  Ribonucleic acid  
RPA  Replication protein A 
RT-PCR Real time PCR 
S phase  Synthesis phase 
SCD  SQ/TQ cluster domain 
SDS  Sodium dodecyl sulfate 
SEM  Standard error of the mean 
SFPQ  Splicing factor, proline- and glutamine-rich 
siRNA  Small interfering RNA 
SMC1  Structural maintenance of chromosomes 1 
SMC3  Structural maintenance of chromosomes 3 
SQ  Serine glutamine 
SSB  Single strand break 
ssDNA  Single stranded DNA 
TBS  Tris buffered saline 
TQ  Threonine glutamine 
Tris  Tris(hydroxymethyl)aminomethane 
UTP  Uridine triphosphate 
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